[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fzBnztHwVpUNK0d2nXG9xdm26qGNhiUcCT1eEIGggMiQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":47,"rows":54},"Sandoz",[4],139,false,3,36,22863,6,7,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"Depression",13,{"name":18,"count":19},"Healthy",11,{"name":21,"count":22},"HIV Infections",10,{"name":24,"count":25},"Hypertension",8,{"name":27,"count":11},"Cytopenias",{"name":29,"count":11},"Rheumatoid Arthritis",{"name":31,"count":32},"Anemia",5,{"name":34,"count":35},"Breast Cancer",4,[37,42],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06153238","A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma","2026-06","GME751",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06847724","Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis","2026-11","CYB704",[48,49,50,51,52,53],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[55,82,100,118,154,172,190,229,264,290,308,333,359,377,425,470,509,531,568,606,624,642,668,686,712,730,755,773,791,817,835,861,879,906,924,942,960,985,1010,1028,1053,1079,1097,1115,1133,1159,1177,1201,1219,1244,1269,1287,1313,1339,1357,1382,1400,1425,1443,1461,1487,1505,1523,1547,1565,1583,1606,1632,1650,1668,1686,1711,1759,1790,1812,1843,1865,1898,1920,1949,1979,2010,2032,2063,2094,2116,2138,2167,2189,2214,2232,2250,2273,2291,2317,2335,2360,2378,2403,2421,2445,2463,2485,2503,2526,2551,2569,2594,2612,2636,2654,2681,2699,2717,2744,2762,2785,2810,2828,2853,2871,2889,2912,2930,2951,2975,2993,3018,3036,3054,3078,3096,3120,3138,3162,3180,3198,3221,3239,3261,3279,3302,3320,3338,3363,3381,3403,3421,3444,3469,3487,3513,3531,3553,3571,3597,3615,3638,3656,3680,3698,3722,3740,3763,3786,3804,3827,3845,3867,3885,3911,3929,3947,3971,3989,4007,4029,4053,4071,4095,4113,4131,4156,4174,4192,4216,4234,4252,4276,4294,4319,4337,4362,4384,4402,4425,4448,4471,4489,4514,4532,4550,4572,4590,4615,4661,4687,4715],{"intervention":46,"totalTrials":56,"cells":57},1,{"EARLY_PHASE1":58,"PHASE1":61,"PHASE2":63,"PHASE3":65,"PHASE4":78,"NA":80},{"trials":59,"activeCount":60},[],0,{"trials":62,"activeCount":60},[],{"trials":64,"activeCount":60},[],{"trials":66,"activeCount":56,"soonestReadout":45},[67],{"nctId":43,"briefTitle":44,"status":68,"phases":69,"primaryCompletion":45,"completion":70,"start":71,"enrollment":72,"conditions":73,"interventions":75},"ACTIVE_NOT_RECRUITING",[51],"2027-05","2025-06-10",183,[74],"Relapsing Multiple Sclerosis",[46,76,77],"Ocrevus-EU","Ocrevus-US",{"trials":79,"activeCount":60},[],{"trials":81,"activeCount":60},[],{"intervention":76,"totalTrials":56,"cells":83},{"EARLY_PHASE1":84,"PHASE1":86,"PHASE2":88,"PHASE3":90,"PHASE4":96,"NA":98},{"trials":85,"activeCount":60},[],{"trials":87,"activeCount":60},[],{"trials":89,"activeCount":60},[],{"trials":91,"activeCount":56,"soonestReadout":45},[92],{"nctId":43,"briefTitle":44,"status":68,"phases":93,"primaryCompletion":45,"completion":70,"start":71,"enrollment":72,"conditions":94,"interventions":95},[51],[74],[46,76,77],{"trials":97,"activeCount":60},[],{"trials":99,"activeCount":60},[],{"intervention":77,"totalTrials":56,"cells":101},{"EARLY_PHASE1":102,"PHASE1":104,"PHASE2":106,"PHASE3":108,"PHASE4":114,"NA":116},{"trials":103,"activeCount":60},[],{"trials":105,"activeCount":60},[],{"trials":107,"activeCount":60},[],{"trials":109,"activeCount":56,"soonestReadout":45},[110],{"nctId":43,"briefTitle":44,"status":68,"phases":111,"primaryCompletion":45,"completion":70,"start":71,"enrollment":72,"conditions":112,"interventions":113},[51],[74],[46,76,77],{"trials":115,"activeCount":60},[],{"trials":117,"activeCount":60},[],{"intervention":41,"totalTrials":119,"cells":120},2,{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":134,"PHASE3":136,"PHASE4":150,"NA":152},{"trials":122,"activeCount":60},[],{"trials":124,"activeCount":56,"soonestReadout":40},[125],{"nctId":38,"briefTitle":39,"status":68,"phases":126,"primaryCompletion":40,"completion":40,"start":127,"enrollment":128,"conditions":129,"interventions":131},[49],"2024-05-15",322,[130],"Melanoma",[41,132,133],"Keytruda - EU","Keytruda - US",{"trials":135,"activeCount":60},[],{"trials":137,"activeCount":60},[138],{"nctId":139,"briefTitle":140,"status":141,"phases":142,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":148},"NCT06159790","A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)","COMPLETED",[51],"2026-03-16","2024-04-29",218,[147],"Metastatic NSCLC",[41,149],"Keytruda-EU",{"trials":151,"activeCount":60},[],{"trials":153,"activeCount":60},[],{"intervention":132,"totalTrials":56,"cells":155},{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":164,"PHASE3":166,"PHASE4":168,"NA":170},{"trials":157,"activeCount":60},[],{"trials":159,"activeCount":56,"soonestReadout":40},[160],{"nctId":38,"briefTitle":39,"status":68,"phases":161,"primaryCompletion":40,"completion":40,"start":127,"enrollment":128,"conditions":162,"interventions":163},[49],[130],[41,132,133],{"trials":165,"activeCount":60},[],{"trials":167,"activeCount":60},[],{"trials":169,"activeCount":60},[],{"trials":171,"activeCount":60},[],{"intervention":133,"totalTrials":56,"cells":173},{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":182,"PHASE3":184,"PHASE4":186,"NA":188},{"trials":175,"activeCount":60},[],{"trials":177,"activeCount":56,"soonestReadout":40},[178],{"nctId":38,"briefTitle":39,"status":68,"phases":179,"primaryCompletion":40,"completion":40,"start":127,"enrollment":128,"conditions":180,"interventions":181},[49],[130],[41,132,133],{"trials":183,"activeCount":60},[],{"trials":185,"activeCount":60},[],{"trials":187,"activeCount":60},[],{"trials":189,"activeCount":60},[],{"intervention":191,"totalTrials":119,"cells":192},"HX575 recombinant human erythropoietin alfa",{"EARLY_PHASE1":193,"PHASE1":195,"PHASE2":197,"PHASE3":199,"PHASE4":214,"NA":227},{"trials":194,"activeCount":60},[],{"trials":196,"activeCount":60},[],{"trials":198,"activeCount":60},[],{"trials":200,"activeCount":60},[201],{"nctId":202,"briefTitle":203,"status":204,"phases":205,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":212},"NCT00701714","Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients","TERMINATED",[51],"2009-07","2010-01","2007-09",337,[31,211],"Chronic Renal Insufficiency",[191,213],"ERYPO",{"trials":215,"activeCount":60},[216],{"nctId":217,"briefTitle":218,"status":141,"phases":219,"primaryCompletion":220,"completion":221,"start":222,"enrollment":223,"conditions":224,"interventions":226},"NCT00632125","Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.",[52],"2010-03","2010-09","2008-07",1695,[225],"Chronic Kidney Disease",[191],{"trials":228,"activeCount":60},[],{"intervention":230,"totalTrials":119,"cells":231},"Filgrastim",{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":250,"NA":262},{"trials":233,"activeCount":60},[],{"trials":235,"activeCount":60},[],{"trials":237,"activeCount":60},[],{"trials":239,"activeCount":60},[240],{"nctId":241,"briefTitle":242,"status":141,"phases":243,"primaryCompletion":244,"completion":244,"start":245,"enrollment":145,"conditions":246,"interventions":248},"NCT01519700","Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim",[51],"2013-06","2011-12",[247,34],"Chemotherapy Associated Neutropenia",[249,230],"EP2006",{"trials":251,"activeCount":60},[252],{"nctId":253,"briefTitle":254,"status":204,"phases":255,"primaryCompletion":256,"completion":257,"start":258,"enrollment":11,"conditions":259,"interventions":261},"NCT01859637","Immunogenicity, Safety, and Efficacy of Zarzio®\u002FFilgrastim HEXAL® in Patients With Severe Chronic Neutropenia",[52],"2014-03","2015-09","2011-07",[260],"Severe Chronic Neutropenia",[230],{"trials":263,"activeCount":60},[],{"intervention":265,"totalTrials":56,"cells":266},"pramipexole",{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":271,"PHASE3":273,"PHASE4":275,"NA":288},{"trials":268,"activeCount":60},[],{"trials":270,"activeCount":60},[],{"trials":272,"activeCount":60},[],{"trials":274,"activeCount":60},[],{"trials":276,"activeCount":60},[277],{"nctId":278,"briefTitle":279,"status":141,"phases":280,"primaryCompletion":281,"completion":281,"start":282,"enrollment":283,"conditions":284,"interventions":286},"NCT01673724","Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease",[52],"2016-05-23","2012-02",121,[285],"Parkinson's Disease",[265,287],"Bromocriptine",{"trials":289,"activeCount":60},[],{"intervention":287,"totalTrials":56,"cells":291},{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":296,"PHASE3":298,"PHASE4":300,"NA":306},{"trials":293,"activeCount":60},[],{"trials":295,"activeCount":60},[],{"trials":297,"activeCount":60},[],{"trials":299,"activeCount":60},[],{"trials":301,"activeCount":60},[302],{"nctId":278,"briefTitle":279,"status":141,"phases":303,"primaryCompletion":281,"completion":281,"start":282,"enrollment":283,"conditions":304,"interventions":305},[52],[285],[265,287],{"trials":307,"activeCount":60},[],{"intervention":309,"totalTrials":56,"cells":310},"Omnitrope",{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":319,"NA":331},{"trials":312,"activeCount":60},[],{"trials":314,"activeCount":60},[],{"trials":316,"activeCount":60},[],{"trials":318,"activeCount":60},[],{"trials":320,"activeCount":60},[321],{"nctId":322,"briefTitle":323,"status":141,"phases":324,"primaryCompletion":325,"completion":325,"start":326,"enrollment":327,"conditions":328,"interventions":330},"NCT00537914","Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)",[52],"2022-03-25","2008-02-06",278,[329],"Small for Gestational Age",[309],{"trials":332,"activeCount":60},[],{"intervention":334,"totalTrials":56,"cells":335},"Levodopa\u002FCarbidopa",{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":340,"PHASE3":342,"PHASE4":344,"NA":357},{"trials":337,"activeCount":60},[],{"trials":339,"activeCount":60},[],{"trials":341,"activeCount":60},[],{"trials":343,"activeCount":60},[],{"trials":345,"activeCount":60},[346],{"nctId":347,"briefTitle":348,"status":141,"phases":349,"primaryCompletion":350,"completion":350,"start":351,"enrollment":352,"conditions":353,"interventions":355},"NCT01683253","Remission of ICD by Switching Dopamine Agonist to Levodopa\u002FCarbidopa",[52],"2014-12","2012-11",150,[354],"Impulse Control Disorder",[334,356],"Dopaminergic Agonists",{"trials":358,"activeCount":60},[],{"intervention":356,"totalTrials":56,"cells":360},{"EARLY_PHASE1":361,"PHASE1":363,"PHASE2":365,"PHASE3":367,"PHASE4":369,"NA":375},{"trials":362,"activeCount":60},[],{"trials":364,"activeCount":60},[],{"trials":366,"activeCount":60},[],{"trials":368,"activeCount":60},[],{"trials":370,"activeCount":60},[371],{"nctId":347,"briefTitle":348,"status":141,"phases":372,"primaryCompletion":350,"completion":350,"start":351,"enrollment":352,"conditions":373,"interventions":374},[52],[354],[334,356],{"trials":376,"activeCount":60},[],{"intervention":378,"totalTrials":8,"cells":379},"GP2013",{"EARLY_PHASE1":380,"PHASE1":382,"PHASE2":393,"PHASE3":407,"PHASE4":421,"NA":423},{"trials":381,"activeCount":60},[],{"trials":383,"activeCount":60},[384],{"nctId":385,"briefTitle":386,"status":141,"phases":387,"primaryCompletion":388,"completion":388,"start":389,"enrollment":11,"conditions":390,"interventions":392},"NCT01933516","GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma",[49],"2014-08","2013-05",[391],"Indolent B-cell Non-Hodgkin's Lymphoma",[378],{"trials":394,"activeCount":60},[395],{"nctId":396,"briefTitle":397,"status":141,"phases":398,"primaryCompletion":399,"completion":400,"start":401,"enrollment":402,"conditions":403,"interventions":404},"NCT01274182","GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy",[49,50],"2016-01","2016-11","2011-01",312,[29],[378,405,406],"MabThera","Rituxan",{"trials":408,"activeCount":60},[409],{"nctId":410,"briefTitle":411,"status":141,"phases":412,"primaryCompletion":413,"completion":414,"start":415,"enrollment":416,"conditions":417,"interventions":419},"NCT01419665","GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)",[51],"2015-07-10","2018-01-22","2011-12-01",629,[418],"Follicular Lymphoma",[378,420],"rituximab",{"trials":422,"activeCount":60},[],{"trials":424,"activeCount":60},[],{"intervention":426,"totalTrials":8,"cells":427},"SOK583A1",{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":432,"PHASE3":434,"PHASE4":466,"NA":468},{"trials":429,"activeCount":60},[],{"trials":431,"activeCount":60},[],{"trials":433,"activeCount":60},[],{"trials":435,"activeCount":60},[436,445,457],{"nctId":437,"briefTitle":438,"status":141,"phases":439,"primaryCompletion":440,"completion":440,"start":441,"enrollment":9,"conditions":442,"interventions":444},"NCT05282004","Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit",[51],"2022-09-07","2022-05-16",[443],"Neovascular Age-related Macular Degeneration (nAMD)",[426],{"nctId":446,"briefTitle":447,"status":141,"phases":448,"primaryCompletion":449,"completion":450,"start":451,"enrollment":452,"conditions":453,"interventions":455},"NCT04864834","Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration",[51],"2022-07-07","2023-05-10","2021-05-12",485,[454],"Neovascular Age-related Macular Degeneration",[426,456],"Eylea EU",{"nctId":458,"briefTitle":459,"status":141,"phases":460,"primaryCompletion":461,"completion":461,"start":462,"enrollment":463,"conditions":464,"interventions":465},"NCT05161806","Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe",[51],"2022-05-04","2022-03-11",30,[443],[426],{"trials":467,"activeCount":60},[],{"trials":469,"activeCount":60},[],{"intervention":471,"totalTrials":119,"cells":472},"LA-EP2006",{"EARLY_PHASE1":473,"PHASE1":475,"PHASE2":477,"PHASE3":479,"PHASE4":505,"NA":507},{"trials":474,"activeCount":60},[],{"trials":476,"activeCount":60},[],{"trials":478,"activeCount":60},[],{"trials":480,"activeCount":60},[481,495],{"nctId":482,"briefTitle":483,"status":141,"phases":484,"primaryCompletion":389,"completion":485,"start":486,"enrollment":487,"conditions":488,"interventions":493},"NCT01735175","Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®",[51],"2014-02","2012-06",316,[489,490,491,492],"Neutropenic Complications","Breast Neoplasms","Chemotherapy-induced Neutropenia","Chemotherapeutic Toxicity",[471,494],"Neulasta®",{"nctId":496,"briefTitle":497,"status":141,"phases":498,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":503,"interventions":504},"NCT01516736","Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim",[51],"2013-08","2013-12","2012-03",308,[491,34],[471,494],{"trials":506,"activeCount":60},[],{"trials":508,"activeCount":60},[],{"intervention":494,"totalTrials":119,"cells":510},{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":517,"PHASE4":527,"NA":529},{"trials":512,"activeCount":60},[],{"trials":514,"activeCount":60},[],{"trials":516,"activeCount":60},[],{"trials":518,"activeCount":60},[519,523],{"nctId":482,"briefTitle":483,"status":141,"phases":520,"primaryCompletion":389,"completion":485,"start":486,"enrollment":487,"conditions":521,"interventions":522},[51],[489,490,491,492],[471,494],{"nctId":496,"briefTitle":497,"status":141,"phases":524,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":525,"interventions":526},[51],[491,34],[471,494],{"trials":528,"activeCount":60},[],{"trials":530,"activeCount":60},[],{"intervention":532,"totalTrials":119,"cells":533},"HX575 epoetin alfa",{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":540,"PHASE4":564,"NA":566},{"trials":535,"activeCount":60},[],{"trials":537,"activeCount":60},[],{"trials":539,"activeCount":60},[],{"trials":541,"activeCount":60},[542,554],{"nctId":543,"briefTitle":544,"status":141,"phases":545,"primaryCompletion":546,"completion":547,"start":548,"enrollment":549,"conditions":550,"interventions":552},"NCT01693029","Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa",[51],"2014-05","2015-03","2012-09",435,[31,551],"Chronic Kidney Disease (CKD)",[532,553],"US-licensed epoetin alfa",{"nctId":555,"briefTitle":556,"status":141,"phases":557,"primaryCompletion":558,"completion":559,"start":560,"enrollment":561,"conditions":562,"interventions":563},"NCT01576341","HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)",[51],"2014-10","2015-06","2012-04",417,[225],[532],{"trials":565,"activeCount":60},[],{"trials":567,"activeCount":60},[],{"intervention":569,"totalTrials":119,"cells":570},"acetylcysteine",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":602,"NA":604},{"trials":572,"activeCount":60},[],{"trials":574,"activeCount":60},[],{"trials":576,"activeCount":60},[],{"trials":578,"activeCount":60},[579,589],{"nctId":580,"briefTitle":581,"status":141,"phases":582,"primaryCompletion":583,"completion":583,"start":584,"enrollment":585,"conditions":586,"interventions":588},"NCT04123405","Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis",[51],"2021-04-20","2020-10-22",944,[587],"Rhinosinusitis",[569],{"nctId":590,"briefTitle":591,"status":592,"phases":593,"primaryCompletion":594,"completion":594,"start":595,"enrollment":60,"conditions":596,"interventions":598},"NCT05070650","Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold","WITHDRAWN",[51],"2025-04-30","2024-09-20",[597],"Common Cold",[599,600,601],"Acetylcysteine","Paracetamol","Phenylephrine",{"trials":603,"activeCount":60},[],{"trials":605,"activeCount":60},[],{"intervention":213,"totalTrials":56,"cells":607},{"EARLY_PHASE1":608,"PHASE1":610,"PHASE2":612,"PHASE3":614,"PHASE4":620,"NA":622},{"trials":609,"activeCount":60},[],{"trials":611,"activeCount":60},[],{"trials":613,"activeCount":60},[],{"trials":615,"activeCount":60},[616],{"nctId":202,"briefTitle":203,"status":204,"phases":617,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":618,"interventions":619},[51],[31,211],[191,213],{"trials":621,"activeCount":60},[],{"trials":623,"activeCount":60},[],{"intervention":553,"totalTrials":56,"cells":625},{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":630,"PHASE3":632,"PHASE4":638,"NA":640},{"trials":627,"activeCount":60},[],{"trials":629,"activeCount":60},[],{"trials":631,"activeCount":60},[],{"trials":633,"activeCount":60},[634],{"nctId":543,"briefTitle":544,"status":141,"phases":635,"primaryCompletion":546,"completion":547,"start":548,"enrollment":549,"conditions":636,"interventions":637},[51],[31,551],[532,553],{"trials":639,"activeCount":60},[],{"trials":641,"activeCount":60},[],{"intervention":643,"totalTrials":56,"cells":644},"Azelastine + Mometazone, nasal spray",{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":651,"PHASE4":664,"NA":666},{"trials":646,"activeCount":60},[],{"trials":648,"activeCount":60},[],{"trials":650,"activeCount":60},[],{"trials":652,"activeCount":60},[653],{"nctId":654,"briefTitle":655,"status":141,"phases":656,"primaryCompletion":657,"completion":657,"start":658,"enrollment":659,"conditions":660,"interventions":662},"NCT05590598","Efficacy and Safety of Azelastine +Mometasone , Nasal Spray, 140 mcg + 50 mcg, (Sandoz d.d., Slovenia) and Momat Rino Advance, Nasal Spray, 140 mcg + 50 mcg, (Glenmark, India) Administered as a Monotherapy to Patients With Seasonal Allergic Rhinitis.",[51],"2023-06-14","2023-02-13",472,[661],"Seasonal Allergic Rhinitis",[643,663],"Momat Rhino Advance",{"trials":665,"activeCount":60},[],{"trials":667,"activeCount":60},[],{"intervention":663,"totalTrials":56,"cells":669},{"EARLY_PHASE1":670,"PHASE1":672,"PHASE2":674,"PHASE3":676,"PHASE4":682,"NA":684},{"trials":671,"activeCount":60},[],{"trials":673,"activeCount":60},[],{"trials":675,"activeCount":60},[],{"trials":677,"activeCount":60},[678],{"nctId":654,"briefTitle":655,"status":141,"phases":679,"primaryCompletion":657,"completion":657,"start":658,"enrollment":659,"conditions":680,"interventions":681},[51],[661],[643,663],{"trials":683,"activeCount":60},[],{"trials":685,"activeCount":60},[],{"intervention":687,"totalTrials":56,"cells":688},"Angal, lozenges [menthol],",{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":695,"PHASE4":708,"NA":710},{"trials":690,"activeCount":60},[],{"trials":692,"activeCount":60},[],{"trials":694,"activeCount":60},[],{"trials":696,"activeCount":60},[697],{"nctId":698,"briefTitle":699,"status":141,"phases":700,"primaryCompletion":701,"completion":701,"start":702,"enrollment":703,"conditions":704,"interventions":706},"NCT03095521","A Local Clinical Study for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol] and ANTI-ANGIN® FORMULA, Lozenges, in Treatment of Patients With a Sore Throat",[51],"2017-05-07","2017-02-22",228,[705],"Sore Throat",[687,707],"ANTI-ANGIN® FORMULA",{"trials":709,"activeCount":60},[],{"trials":711,"activeCount":60},[],{"intervention":707,"totalTrials":56,"cells":713},{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":720,"PHASE4":726,"NA":728},{"trials":715,"activeCount":60},[],{"trials":717,"activeCount":60},[],{"trials":719,"activeCount":60},[],{"trials":721,"activeCount":60},[722],{"nctId":698,"briefTitle":699,"status":141,"phases":723,"primaryCompletion":701,"completion":701,"start":702,"enrollment":703,"conditions":724,"interventions":725},[51],[705],[687,707],{"trials":727,"activeCount":60},[],{"trials":729,"activeCount":60},[],{"intervention":731,"totalTrials":56,"cells":732},"Mometasone",{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":739,"PHASE4":751,"NA":753},{"trials":734,"activeCount":60},[],{"trials":736,"activeCount":60},[],{"trials":738,"activeCount":60},[],{"trials":740,"activeCount":60},[741],{"nctId":742,"briefTitle":743,"status":141,"phases":744,"primaryCompletion":745,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":749},"NCT05311475","Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic Rhinitis",[51],"2023-06-20","2022-04-04",669,[661],[731,750],"Azelastine",{"trials":752,"activeCount":60},[],{"trials":754,"activeCount":60},[],{"intervention":750,"totalTrials":56,"cells":756},{"EARLY_PHASE1":757,"PHASE1":759,"PHASE2":761,"PHASE3":763,"PHASE4":769,"NA":771},{"trials":758,"activeCount":60},[],{"trials":760,"activeCount":60},[],{"trials":762,"activeCount":60},[],{"trials":764,"activeCount":60},[765],{"nctId":742,"briefTitle":743,"status":141,"phases":766,"primaryCompletion":745,"completion":745,"start":746,"enrollment":747,"conditions":767,"interventions":768},[51],[661],[731,750],{"trials":770,"activeCount":60},[],{"trials":772,"activeCount":60},[],{"intervention":249,"totalTrials":56,"cells":774},{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":781,"PHASE4":787,"NA":789},{"trials":776,"activeCount":60},[],{"trials":778,"activeCount":60},[],{"trials":780,"activeCount":60},[],{"trials":782,"activeCount":60},[783],{"nctId":241,"briefTitle":242,"status":141,"phases":784,"primaryCompletion":244,"completion":244,"start":245,"enrollment":145,"conditions":785,"interventions":786},[51],[247,34],[249,230],{"trials":788,"activeCount":60},[],{"trials":790,"activeCount":60},[],{"intervention":792,"totalTrials":56,"cells":793},"Mesalamine",{"EARLY_PHASE1":794,"PHASE1":796,"PHASE2":798,"PHASE3":800,"PHASE4":813,"NA":815},{"trials":795,"activeCount":60},[],{"trials":797,"activeCount":60},[],{"trials":799,"activeCount":60},[],{"trials":801,"activeCount":60},[802],{"nctId":803,"briefTitle":804,"status":204,"phases":805,"primaryCompletion":806,"completion":806,"start":807,"enrollment":808,"conditions":809,"interventions":811},"NCT01172444","Clinical Trial With Mesalamine 1g Suppositories",[51],"2012-12","2010-06",158,[810],"Proctitis",[792,812],"Canasa",{"trials":814,"activeCount":60},[],{"trials":816,"activeCount":60},[],{"intervention":812,"totalTrials":56,"cells":818},{"EARLY_PHASE1":819,"PHASE1":821,"PHASE2":823,"PHASE3":825,"PHASE4":831,"NA":833},{"trials":820,"activeCount":60},[],{"trials":822,"activeCount":60},[],{"trials":824,"activeCount":60},[],{"trials":826,"activeCount":60},[827],{"nctId":803,"briefTitle":804,"status":204,"phases":828,"primaryCompletion":806,"completion":806,"start":807,"enrollment":808,"conditions":829,"interventions":830},[51],[810],[792,812],{"trials":832,"activeCount":60},[],{"trials":834,"activeCount":60},[],{"intervention":836,"totalTrials":56,"cells":837},"Mometasone furoate 50 mcg\u002Factuation nasal spray",{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":844,"PHASE4":857,"NA":859},{"trials":839,"activeCount":60},[],{"trials":841,"activeCount":60},[],{"trials":843,"activeCount":60},[],{"trials":845,"activeCount":60},[846],{"nctId":847,"briefTitle":848,"status":141,"phases":849,"primaryCompletion":850,"completion":850,"start":851,"enrollment":852,"conditions":853,"interventions":855},"NCT01038427","A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis",[51],"2010-02-16","2009-12-02",795,[854],"Rhinitis, Allergic, Seasonal",[836,856],"Mometasone furoate (Nasonex®) 50 mcg\u002Factuation nasal spray",{"trials":858,"activeCount":60},[],{"trials":860,"activeCount":60},[],{"intervention":856,"totalTrials":56,"cells":862},{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":867,"PHASE3":869,"PHASE4":875,"NA":877},{"trials":864,"activeCount":60},[],{"trials":866,"activeCount":60},[],{"trials":868,"activeCount":60},[],{"trials":870,"activeCount":60},[871],{"nctId":847,"briefTitle":848,"status":141,"phases":872,"primaryCompletion":850,"completion":850,"start":851,"enrollment":852,"conditions":873,"interventions":874},[51],[854],[836,856],{"trials":876,"activeCount":60},[],{"trials":878,"activeCount":60},[],{"intervention":880,"totalTrials":56,"cells":881},"JPB898",{"EARLY_PHASE1":882,"PHASE1":884,"PHASE2":886,"PHASE3":888,"PHASE4":902,"NA":904},{"trials":883,"activeCount":60},[],{"trials":885,"activeCount":60},[],{"trials":887,"activeCount":60},[],{"trials":889,"activeCount":60},[890],{"nctId":891,"briefTitle":892,"status":204,"phases":893,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":897,"interventions":898},"NCT06587451","Integrated Pharmacokinetics (PK)\u002FEfficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®",[51],"2026-01-23","2024-12-19",52,[130],[880,899,900,901,899],"Opdivo-EU","Opdivo-US","Yervoy-EU",{"trials":903,"activeCount":60},[],{"trials":905,"activeCount":60},[],{"intervention":899,"totalTrials":56,"cells":907},{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":912,"PHASE3":914,"PHASE4":920,"NA":922},{"trials":909,"activeCount":60},[],{"trials":911,"activeCount":60},[],{"trials":913,"activeCount":60},[],{"trials":915,"activeCount":60},[916],{"nctId":891,"briefTitle":892,"status":204,"phases":917,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":918,"interventions":919},[51],[130],[880,899,900,901,899],{"trials":921,"activeCount":60},[],{"trials":923,"activeCount":60},[],{"intervention":900,"totalTrials":56,"cells":925},{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":930,"PHASE3":932,"PHASE4":938,"NA":940},{"trials":927,"activeCount":60},[],{"trials":929,"activeCount":60},[],{"trials":931,"activeCount":60},[],{"trials":933,"activeCount":60},[934],{"nctId":891,"briefTitle":892,"status":204,"phases":935,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":936,"interventions":937},[51],[130],[880,899,900,901,899],{"trials":939,"activeCount":60},[],{"trials":941,"activeCount":60},[],{"intervention":901,"totalTrials":56,"cells":943},{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":950,"PHASE4":956,"NA":958},{"trials":945,"activeCount":60},[],{"trials":947,"activeCount":60},[],{"trials":949,"activeCount":60},[],{"trials":951,"activeCount":60},[952],{"nctId":891,"briefTitle":892,"status":204,"phases":953,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":954,"interventions":955},[51],[130],[880,899,900,901,899],{"trials":957,"activeCount":60},[],{"trials":959,"activeCount":60},[],{"intervention":961,"totalTrials":56,"cells":962},"GP2015",{"EARLY_PHASE1":963,"PHASE1":965,"PHASE2":967,"PHASE3":969,"PHASE4":981,"NA":983},{"trials":964,"activeCount":60},[],{"trials":966,"activeCount":60},[],{"trials":968,"activeCount":60},[],{"trials":970,"activeCount":60},[971],{"nctId":972,"briefTitle":973,"status":141,"phases":974,"primaryCompletion":975,"completion":976,"start":977,"enrollment":978,"conditions":979,"interventions":980},"NCT02638259","Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis",[51],"2016-12-29","2017-06-12","2015-02-21",376,[29],[961],{"trials":982,"activeCount":60},[],{"trials":984,"activeCount":60},[],{"intervention":986,"totalTrials":56,"cells":987},"Fluticasone furoate 27.5 mcg\u002Factuation nasal spray",{"EARLY_PHASE1":988,"PHASE1":990,"PHASE2":992,"PHASE3":994,"PHASE4":1006,"NA":1008},{"trials":989,"activeCount":60},[],{"trials":991,"activeCount":60},[],{"trials":993,"activeCount":60},[],{"trials":995,"activeCount":60},[996],{"nctId":997,"briefTitle":998,"status":141,"phases":999,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1003,"interventions":1004},"NCT01279057","A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis",[51],"2011-02-08","2010-12-27",727,[854],[986,1005],"Fluticasone furoate (Veramyst®) 27.5 mcg\u002Factuation nasal spray",{"trials":1007,"activeCount":60},[],{"trials":1009,"activeCount":60},[],{"intervention":1005,"totalTrials":56,"cells":1011},{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1018,"PHASE4":1024,"NA":1026},{"trials":1013,"activeCount":60},[],{"trials":1015,"activeCount":60},[],{"trials":1017,"activeCount":60},[],{"trials":1019,"activeCount":60},[1020],{"nctId":997,"briefTitle":998,"status":141,"phases":1021,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1022,"interventions":1023},[51],[854],[986,1005],{"trials":1025,"activeCount":60},[],{"trials":1027,"activeCount":60},[],{"intervention":1029,"totalTrials":56,"cells":1030},"Broncho-munal®",{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1035,"PHASE3":1037,"PHASE4":1049,"NA":1051},{"trials":1032,"activeCount":60},[],{"trials":1034,"activeCount":60},[],{"trials":1036,"activeCount":60},[],{"trials":1038,"activeCount":60},[1039],{"nctId":1040,"briefTitle":1041,"status":141,"phases":1042,"primaryCompletion":1043,"completion":1043,"start":1044,"enrollment":1045,"conditions":1046,"interventions":1048},"NCT05588804","Study of the Efficacy and Safety of Broncho-munal®, Capsules, 7 mg for the Treatment of Acute Uncomplicated Respiratory Tract Infections",[51],"2022-12-18","2022-11-07",556,[1047],"Acute Uncomplicated Respiratory Tract Infections",[1029],{"trials":1050,"activeCount":60},[],{"trials":1052,"activeCount":60},[],{"intervention":1054,"totalTrials":56,"cells":1055},"Adalimumab - GP2017",{"EARLY_PHASE1":1056,"PHASE1":1058,"PHASE2":1060,"PHASE3":1062,"PHASE4":1075,"NA":1077},{"trials":1057,"activeCount":60},[],{"trials":1059,"activeCount":60},[],{"trials":1061,"activeCount":60},[],{"trials":1063,"activeCount":60},[1064],{"nctId":1065,"briefTitle":1066,"status":141,"phases":1067,"primaryCompletion":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":1072,"interventions":1073},"NCT02744755","Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis",[51],"2017-01-31","2017-09-26","2016-03-31",353,[29],[1054,1074],"Adalimumab - US licensed Humira",{"trials":1076,"activeCount":60},[],{"trials":1078,"activeCount":60},[],{"intervention":1074,"totalTrials":56,"cells":1080},{"EARLY_PHASE1":1081,"PHASE1":1083,"PHASE2":1085,"PHASE3":1087,"PHASE4":1093,"NA":1095},{"trials":1082,"activeCount":60},[],{"trials":1084,"activeCount":60},[],{"trials":1086,"activeCount":60},[],{"trials":1088,"activeCount":60},[1089],{"nctId":1065,"briefTitle":1066,"status":141,"phases":1090,"primaryCompletion":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":1091,"interventions":1092},[51],[29],[1054,1074],{"trials":1094,"activeCount":60},[],{"trials":1096,"activeCount":60},[],{"intervention":600,"totalTrials":56,"cells":1098},{"EARLY_PHASE1":1099,"PHASE1":1101,"PHASE2":1103,"PHASE3":1105,"PHASE4":1111,"NA":1113},{"trials":1100,"activeCount":60},[],{"trials":1102,"activeCount":60},[],{"trials":1104,"activeCount":60},[],{"trials":1106,"activeCount":60},[1107],{"nctId":590,"briefTitle":591,"status":592,"phases":1108,"primaryCompletion":594,"completion":594,"start":595,"enrollment":60,"conditions":1109,"interventions":1110},[51],[597],[599,600,601],{"trials":1112,"activeCount":60},[],{"trials":1114,"activeCount":60},[],{"intervention":601,"totalTrials":56,"cells":1116},{"EARLY_PHASE1":1117,"PHASE1":1119,"PHASE2":1121,"PHASE3":1123,"PHASE4":1129,"NA":1131},{"trials":1118,"activeCount":60},[],{"trials":1120,"activeCount":60},[],{"trials":1122,"activeCount":60},[],{"trials":1124,"activeCount":60},[1125],{"nctId":590,"briefTitle":591,"status":592,"phases":1126,"primaryCompletion":594,"completion":594,"start":595,"enrollment":60,"conditions":1127,"interventions":1128},[51],[597],[599,600,601],{"trials":1130,"activeCount":60},[],{"trials":1132,"activeCount":60},[],{"intervention":1134,"totalTrials":56,"cells":1135},"GP2017 Adalimumab",{"EARLY_PHASE1":1136,"PHASE1":1138,"PHASE2":1140,"PHASE3":1142,"PHASE4":1155,"NA":1157},{"trials":1137,"activeCount":60},[],{"trials":1139,"activeCount":60},[],{"trials":1141,"activeCount":60},[],{"trials":1143,"activeCount":60},[1144],{"nctId":1145,"briefTitle":1146,"status":141,"phases":1147,"primaryCompletion":1148,"completion":1149,"start":500,"enrollment":1150,"conditions":1151,"interventions":1153},"NCT02016105","Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira",[51],"2015-07","2016-02",465,[1152],"Plaque Type Psoriasis",[1134,1154],"Humira ® Adalimumab",{"trials":1156,"activeCount":60},[],{"trials":1158,"activeCount":60},[],{"intervention":1154,"totalTrials":56,"cells":1160},{"EARLY_PHASE1":1161,"PHASE1":1163,"PHASE2":1165,"PHASE3":1167,"PHASE4":1173,"NA":1175},{"trials":1162,"activeCount":60},[],{"trials":1164,"activeCount":60},[],{"trials":1166,"activeCount":60},[],{"trials":1168,"activeCount":60},[1169],{"nctId":1145,"briefTitle":1146,"status":141,"phases":1170,"primaryCompletion":1148,"completion":1149,"start":500,"enrollment":1150,"conditions":1171,"interventions":1172},[51],[1152],[1134,1154],{"trials":1174,"activeCount":60},[],{"trials":1176,"activeCount":60},[],{"intervention":1178,"totalTrials":56,"cells":1179},"Fluticasone furoate and vilanterol inhalation powder",{"EARLY_PHASE1":1180,"PHASE1":1182,"PHASE2":1184,"PHASE3":1186,"PHASE4":1197,"NA":1199},{"trials":1181,"activeCount":60},[],{"trials":1183,"activeCount":60},[],{"trials":1185,"activeCount":60},[],{"trials":1187,"activeCount":60},[1188],{"nctId":1189,"briefTitle":1190,"status":592,"phases":1191,"primaryCompletion":1192,"completion":1192,"start":1192,"enrollment":60,"conditions":1193,"interventions":1195},"NCT07223294","Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg\u002F25 mcg and BREO ELLIPTA 100 mcg\u002F25 mcg in Participants With Asthma",[51],"2026-04-21",[1194],"Respiratory",[1178,1196],"Breo Ellipta",{"trials":1198,"activeCount":60},[],{"trials":1200,"activeCount":60},[],{"intervention":1196,"totalTrials":56,"cells":1202},{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1209,"PHASE4":1215,"NA":1217},{"trials":1204,"activeCount":60},[],{"trials":1206,"activeCount":60},[],{"trials":1208,"activeCount":60},[],{"trials":1210,"activeCount":60},[1211],{"nctId":1189,"briefTitle":1190,"status":592,"phases":1212,"primaryCompletion":1192,"completion":1192,"start":1192,"enrollment":60,"conditions":1213,"interventions":1214},[51],[1194],[1178,1196],{"trials":1216,"activeCount":60},[],{"trials":1218,"activeCount":60},[],{"intervention":1220,"totalTrials":56,"cells":1221},"LRG-002",{"EARLY_PHASE1":1222,"PHASE1":1224,"PHASE2":1226,"PHASE3":1228,"PHASE4":1240,"NA":1242},{"trials":1223,"activeCount":60},[],{"trials":1225,"activeCount":60},[],{"trials":1227,"activeCount":60},[],{"trials":1229,"activeCount":60},[1230],{"nctId":1231,"briefTitle":1232,"status":141,"phases":1233,"primaryCompletion":1234,"completion":1234,"start":1235,"enrollment":1236,"conditions":1237,"interventions":1239},"NCT04321460","Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults.",[51],"2021-01-04","2020-10-01",520,[1238],"Antibiotic-associated Diarrhea",[1220],{"trials":1241,"activeCount":60},[],{"trials":1243,"activeCount":60},[],{"intervention":1245,"totalTrials":56,"cells":1246},"GP2013 - A Proposed biosimilar rituximab",{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1251,"PHASE3":1253,"PHASE4":1265,"NA":1267},{"trials":1248,"activeCount":60},[],{"trials":1250,"activeCount":60},[],{"trials":1252,"activeCount":60},[],{"trials":1254,"activeCount":60},[1255],{"nctId":1256,"briefTitle":1257,"status":141,"phases":1258,"primaryCompletion":1259,"completion":1260,"start":1148,"enrollment":1261,"conditions":1262,"interventions":1263},"NCT02514772","GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®",[51],"2016-07","2016-10",107,[29],[1245,1264],"Originator rituximab - Rituxan ® or MabThera ®",{"trials":1266,"activeCount":60},[],{"trials":1268,"activeCount":60},[],{"intervention":1264,"totalTrials":56,"cells":1270},{"EARLY_PHASE1":1271,"PHASE1":1273,"PHASE2":1275,"PHASE3":1277,"PHASE4":1283,"NA":1285},{"trials":1272,"activeCount":60},[],{"trials":1274,"activeCount":60},[],{"trials":1276,"activeCount":60},[],{"trials":1278,"activeCount":60},[1279],{"nctId":1256,"briefTitle":1257,"status":141,"phases":1280,"primaryCompletion":1259,"completion":1260,"start":1148,"enrollment":1261,"conditions":1281,"interventions":1282},[51],[29],[1245,1264],{"trials":1284,"activeCount":60},[],{"trials":1286,"activeCount":60},[],{"intervention":1288,"totalTrials":56,"cells":1289},"Rifaximin (Sandoz GmbH)",{"EARLY_PHASE1":1290,"PHASE1":1292,"PHASE2":1294,"PHASE3":1296,"PHASE4":1309,"NA":1311},{"trials":1291,"activeCount":60},[],{"trials":1293,"activeCount":60},[],{"trials":1295,"activeCount":60},[],{"trials":1297,"activeCount":60},[1298],{"nctId":1299,"briefTitle":1300,"status":204,"phases":1301,"primaryCompletion":1302,"completion":1302,"start":1303,"enrollment":1304,"conditions":1305,"interventions":1307},"NCT02920242","A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.",[51],"2017-05-23","2016-12-15",28,[1306],"Travelers' Diarrhea",[1288,1308],"Rifaximin",{"trials":1310,"activeCount":60},[],{"trials":1312,"activeCount":60},[],{"intervention":1314,"totalTrials":56,"cells":1315},"HX575, solution for",{"EARLY_PHASE1":1316,"PHASE1":1318,"PHASE2":1320,"PHASE3":1322,"PHASE4":1335,"NA":1337},{"trials":1317,"activeCount":60},[],{"trials":1319,"activeCount":60},[],{"trials":1321,"activeCount":60},[],{"trials":1323,"activeCount":60},[1324],{"nctId":1325,"briefTitle":1326,"status":141,"phases":1327,"primaryCompletion":1328,"completion":1329,"start":1330,"enrollment":1331,"conditions":1332,"interventions":1333},"NCT00711958","Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients",[51],"2005-07","2005-12","2004-11",114,[31],[1314,1334],"ERYPO®, Janssen-Cilag, solution for",{"trials":1336,"activeCount":60},[],{"trials":1338,"activeCount":60},[],{"intervention":1334,"totalTrials":56,"cells":1340},{"EARLY_PHASE1":1341,"PHASE1":1343,"PHASE2":1345,"PHASE3":1347,"PHASE4":1353,"NA":1355},{"trials":1342,"activeCount":60},[],{"trials":1344,"activeCount":60},[],{"trials":1346,"activeCount":60},[],{"trials":1348,"activeCount":60},[1349],{"nctId":1325,"briefTitle":1326,"status":141,"phases":1350,"primaryCompletion":1328,"completion":1329,"start":1330,"enrollment":1331,"conditions":1351,"interventions":1352},[51],[31],[1314,1334],{"trials":1354,"activeCount":60},[],{"trials":1356,"activeCount":60},[],{"intervention":1358,"totalTrials":56,"cells":1359},"HX575 epoetin alfa Hexal AG",{"EARLY_PHASE1":1360,"PHASE1":1362,"PHASE2":1364,"PHASE3":1366,"PHASE4":1378,"NA":1380},{"trials":1361,"activeCount":60},[],{"trials":1363,"activeCount":60},[],{"trials":1365,"activeCount":60},[],{"trials":1367,"activeCount":60},[1368],{"nctId":1369,"briefTitle":1370,"status":141,"phases":1371,"primaryCompletion":1372,"completion":1372,"start":1373,"enrollment":1374,"conditions":1375,"interventions":1376},"NCT00666835","Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients",[51],"2006-01","2004-04",478,[31],[1358,1377],"ERYPO®, Janssen-Cilag",{"trials":1379,"activeCount":60},[],{"trials":1381,"activeCount":60},[],{"intervention":1377,"totalTrials":56,"cells":1383},{"EARLY_PHASE1":1384,"PHASE1":1386,"PHASE2":1388,"PHASE3":1390,"PHASE4":1396,"NA":1398},{"trials":1385,"activeCount":60},[],{"trials":1387,"activeCount":60},[],{"trials":1389,"activeCount":60},[],{"trials":1391,"activeCount":60},[1392],{"nctId":1369,"briefTitle":1370,"status":141,"phases":1393,"primaryCompletion":1372,"completion":1372,"start":1373,"enrollment":1374,"conditions":1394,"interventions":1395},[51],[31],[1358,1377],{"trials":1397,"activeCount":60},[],{"trials":1399,"activeCount":60},[],{"intervention":1401,"totalTrials":56,"cells":1402},"GP2015 Etanercept",{"EARLY_PHASE1":1403,"PHASE1":1405,"PHASE2":1407,"PHASE3":1409,"PHASE4":1421,"NA":1423},{"trials":1404,"activeCount":60},[],{"trials":1406,"activeCount":60},[],{"trials":1408,"activeCount":60},[],{"trials":1410,"activeCount":60},[1411],{"nctId":1412,"briefTitle":1413,"status":141,"phases":1414,"primaryCompletion":1415,"completion":547,"start":244,"enrollment":1416,"conditions":1417,"interventions":1419},"NCT01891864","Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel",[51],"2014-06",531,[1418],"Chronic Stable Plaque Psoriasis",[1401,1420],"Enbrel",{"trials":1422,"activeCount":60},[],{"trials":1424,"activeCount":60},[],{"intervention":1420,"totalTrials":56,"cells":1426},{"EARLY_PHASE1":1427,"PHASE1":1429,"PHASE2":1431,"PHASE3":1433,"PHASE4":1439,"NA":1441},{"trials":1428,"activeCount":60},[],{"trials":1430,"activeCount":60},[],{"trials":1432,"activeCount":60},[],{"trials":1434,"activeCount":60},[1435],{"nctId":1412,"briefTitle":1413,"status":141,"phases":1436,"primaryCompletion":1415,"completion":547,"start":244,"enrollment":1416,"conditions":1437,"interventions":1438},[51],[1418],[1401,1420],{"trials":1440,"activeCount":60},[],{"trials":1442,"activeCount":60},[],{"intervention":149,"totalTrials":56,"cells":1444},{"EARLY_PHASE1":1445,"PHASE1":1447,"PHASE2":1449,"PHASE3":1451,"PHASE4":1457,"NA":1459},{"trials":1446,"activeCount":60},[],{"trials":1448,"activeCount":60},[],{"trials":1450,"activeCount":60},[],{"trials":1452,"activeCount":60},[1453],{"nctId":139,"briefTitle":140,"status":141,"phases":1454,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":1455,"interventions":1456},[51],[147],[41,149],{"trials":1458,"activeCount":60},[],{"trials":1460,"activeCount":60},[],{"intervention":1462,"totalTrials":56,"cells":1463},"GP2411",{"EARLY_PHASE1":1464,"PHASE1":1466,"PHASE2":1468,"PHASE3":1470,"PHASE4":1483,"NA":1485},{"trials":1465,"activeCount":60},[],{"trials":1467,"activeCount":60},[],{"trials":1469,"activeCount":60},[],{"trials":1471,"activeCount":60},[1472],{"nctId":1473,"briefTitle":1474,"status":141,"phases":1475,"primaryCompletion":1476,"completion":1476,"start":1477,"enrollment":1478,"conditions":1479,"interventions":1481},"NCT03974100","Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis",[51],"2022-04-22","2019-07-02",527,[1480],"Postmenopausal Women With Osteoporosis",[1462,1482],"EU-Prolia",{"trials":1484,"activeCount":60},[],{"trials":1486,"activeCount":60},[],{"intervention":1482,"totalTrials":56,"cells":1488},{"EARLY_PHASE1":1489,"PHASE1":1491,"PHASE2":1493,"PHASE3":1495,"PHASE4":1501,"NA":1503},{"trials":1490,"activeCount":60},[],{"trials":1492,"activeCount":60},[],{"trials":1494,"activeCount":60},[],{"trials":1496,"activeCount":60},[1497],{"nctId":1473,"briefTitle":1474,"status":141,"phases":1498,"primaryCompletion":1476,"completion":1476,"start":1477,"enrollment":1478,"conditions":1499,"interventions":1500},[51],[1480],[1462,1482],{"trials":1502,"activeCount":60},[],{"trials":1504,"activeCount":60},[],{"intervention":420,"totalTrials":56,"cells":1506},{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1511,"PHASE3":1513,"PHASE4":1519,"NA":1521},{"trials":1508,"activeCount":60},[],{"trials":1510,"activeCount":60},[],{"trials":1512,"activeCount":60},[],{"trials":1514,"activeCount":60},[1515],{"nctId":410,"briefTitle":411,"status":141,"phases":1516,"primaryCompletion":413,"completion":414,"start":415,"enrollment":416,"conditions":1517,"interventions":1518},[51],[418],[378,420],{"trials":1520,"activeCount":60},[],{"trials":1522,"activeCount":60},[],{"intervention":1524,"totalTrials":56,"cells":1525},"Angal S, topical spray [Menthol]",{"EARLY_PHASE1":1526,"PHASE1":1528,"PHASE2":1530,"PHASE3":1532,"PHASE4":1543,"NA":1545},{"trials":1527,"activeCount":60},[],{"trials":1529,"activeCount":60},[],{"trials":1531,"activeCount":60},[],{"trials":1533,"activeCount":60},[1534],{"nctId":1535,"briefTitle":1536,"status":141,"phases":1537,"primaryCompletion":1538,"completion":1538,"start":702,"enrollment":1539,"conditions":1540,"interventions":1541},"NCT03095508","Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray and ANTI-ANGIN® FORMULA, Topical Metered Spray in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore Throat",[51],"2017-05-08",229,[705],[1524,1542],"ANTI-ANGIN® FORMULA, topical metered spray",{"trials":1544,"activeCount":60},[],{"trials":1546,"activeCount":60},[],{"intervention":1542,"totalTrials":56,"cells":1548},{"EARLY_PHASE1":1549,"PHASE1":1551,"PHASE2":1553,"PHASE3":1555,"PHASE4":1561,"NA":1563},{"trials":1550,"activeCount":60},[],{"trials":1552,"activeCount":60},[],{"trials":1554,"activeCount":60},[],{"trials":1556,"activeCount":60},[1557],{"nctId":1535,"briefTitle":1536,"status":141,"phases":1558,"primaryCompletion":1538,"completion":1538,"start":702,"enrollment":1539,"conditions":1559,"interventions":1560},[51],[705],[1524,1542],{"trials":1562,"activeCount":60},[],{"trials":1564,"activeCount":60},[],{"intervention":456,"totalTrials":56,"cells":1566},{"EARLY_PHASE1":1567,"PHASE1":1569,"PHASE2":1571,"PHASE3":1573,"PHASE4":1579,"NA":1581},{"trials":1568,"activeCount":60},[],{"trials":1570,"activeCount":60},[],{"trials":1572,"activeCount":60},[],{"trials":1574,"activeCount":60},[1575],{"nctId":446,"briefTitle":447,"status":141,"phases":1576,"primaryCompletion":449,"completion":450,"start":451,"enrollment":452,"conditions":1577,"interventions":1578},[51],[454],[426,456],{"trials":1580,"activeCount":60},[],{"trials":1582,"activeCount":60},[],{"intervention":1584,"totalTrials":56,"cells":1585},"HX575 solution for s.c. administration",{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1590,"PHASE3":1592,"PHASE4":1602,"NA":1604},{"trials":1587,"activeCount":60},[],{"trials":1589,"activeCount":60},[],{"trials":1591,"activeCount":60},[],{"trials":1593,"activeCount":60},[1594],{"nctId":1595,"briefTitle":1596,"status":592,"phases":1597,"primaryCompletion":1598,"completion":1598,"start":1599,"enrollment":60,"conditions":1600,"interventions":1601},"NCT00869856","Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)",[51],"2009-08","2009-04",[31,211],[1584],{"trials":1603,"activeCount":60},[],{"trials":1605,"activeCount":60},[],{"intervention":1607,"totalTrials":56,"cells":1608},"Ferrum Lek®",{"EARLY_PHASE1":1609,"PHASE1":1611,"PHASE2":1613,"PHASE3":1615,"PHASE4":1628,"NA":1630},{"trials":1610,"activeCount":60},[],{"trials":1612,"activeCount":60},[],{"trials":1614,"activeCount":60},[],{"trials":1616,"activeCount":60},[1617],{"nctId":1618,"briefTitle":1619,"status":141,"phases":1620,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":1624,"interventions":1626},"NCT03993288","Study to Test the Hypothesis of Non-inferior Efficacy and Safety of Ferrum Lek® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia), as Compared With MALTOFER® (Vifor S.A., Switzerland), in Subjects With Mild and Moderate Iron Deficiency Anemia.",[51],"2020-06-18","2019-06-27",267,[1625],"Mild and Moderate Iron-deficiency Anaemia",[1607,1627],"MALTOFER®",{"trials":1629,"activeCount":60},[],{"trials":1631,"activeCount":60},[],{"intervention":1627,"totalTrials":56,"cells":1633},{"EARLY_PHASE1":1634,"PHASE1":1636,"PHASE2":1638,"PHASE3":1640,"PHASE4":1646,"NA":1648},{"trials":1635,"activeCount":60},[],{"trials":1637,"activeCount":60},[],{"trials":1639,"activeCount":60},[],{"trials":1641,"activeCount":60},[1642],{"nctId":1618,"briefTitle":1619,"status":141,"phases":1643,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":1644,"interventions":1645},[51],[1625],[1607,1627],{"trials":1647,"activeCount":60},[],{"trials":1649,"activeCount":60},[],{"intervention":405,"totalTrials":56,"cells":1651},{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1656,"PHASE3":1662,"PHASE4":1664,"NA":1666},{"trials":1653,"activeCount":60},[],{"trials":1655,"activeCount":60},[],{"trials":1657,"activeCount":60},[1658],{"nctId":396,"briefTitle":397,"status":141,"phases":1659,"primaryCompletion":399,"completion":400,"start":401,"enrollment":402,"conditions":1660,"interventions":1661},[49,50],[29],[378,405,406],{"trials":1663,"activeCount":60},[],{"trials":1665,"activeCount":60},[],{"trials":1667,"activeCount":60},[],{"intervention":406,"totalTrials":56,"cells":1669},{"EARLY_PHASE1":1670,"PHASE1":1672,"PHASE2":1674,"PHASE3":1680,"PHASE4":1682,"NA":1684},{"trials":1671,"activeCount":60},[],{"trials":1673,"activeCount":60},[],{"trials":1675,"activeCount":60},[1676],{"nctId":396,"briefTitle":397,"status":141,"phases":1677,"primaryCompletion":399,"completion":400,"start":401,"enrollment":402,"conditions":1678,"interventions":1679},[49,50],[29],[378,405,406],{"trials":1681,"activeCount":60},[],{"trials":1683,"activeCount":60},[],{"trials":1685,"activeCount":60},[],{"intervention":1687,"totalTrials":56,"cells":1688},"fluticasone propionate\u002Fsalmeterol (Flu\u002FSal) : 100mcg\u002F50mcg, 250mcg\u002F50mcg,500mcg\u002F50 mcg",{"EARLY_PHASE1":1689,"PHASE1":1691,"PHASE2":1693,"PHASE3":1705,"PHASE4":1707,"NA":1709},{"trials":1690,"activeCount":60},[],{"trials":1692,"activeCount":60},[],{"trials":1694,"activeCount":60},[1695],{"nctId":1696,"briefTitle":1697,"status":141,"phases":1698,"primaryCompletion":1699,"completion":1699,"start":1700,"enrollment":1701,"conditions":1702,"interventions":1704},"NCT00927758","Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)\u002FSalmeterol (SAL) Combination Product Advair",[50],"2009-12","2009-06",105,[1703],"Asthma",[1687],{"trials":1706,"activeCount":60},[],{"trials":1708,"activeCount":60},[],{"trials":1710,"activeCount":60},[],{"intervention":1712,"totalTrials":35,"cells":1713},"Cefzil",{"EARLY_PHASE1":1714,"PHASE1":1716,"PHASE2":1751,"PHASE3":1753,"PHASE4":1755,"NA":1757},{"trials":1715,"activeCount":60},[],{"trials":1717,"activeCount":60},[1718,1727,1737,1744],{"nctId":1719,"briefTitle":1720,"status":141,"phases":1721,"primaryCompletion":1373,"completion":1373,"start":1722,"enrollment":1723,"conditions":1724,"interventions":1725},"NCT00881426","To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fasting Conditions",[49],"2004-03",26,[18],[1726,1712],"Cefprozil 500 mg",{"nctId":1728,"briefTitle":1729,"status":141,"phases":1730,"primaryCompletion":1731,"completion":1731,"start":1732,"enrollment":1733,"conditions":1734,"interventions":1735},"NCT00881153","To Demonstrate the Relative Bioavailability of Cefzil 250 mg\u002F5 ml Cefprozil Oral Suspension Following a 10 ml Dose Fasting Conditions.",[49],"2004-06","2004-05",20,[18],[1736,1712],"Cefprozil 250 mg\u002F5 ml Oral Suspension",{"nctId":1738,"briefTitle":1739,"status":141,"phases":1740,"primaryCompletion":1731,"completion":1731,"start":1731,"enrollment":1741,"conditions":1742,"interventions":1743},"NCT00881400","To Demonstrate the Relative Bioavailability of Cefzil 250 mg\u002F5 ml Cefprozil Oral Suspension Fed Conditions",[49],24,[18],[1736,1712],{"nctId":1745,"briefTitle":1746,"status":141,"phases":1747,"primaryCompletion":1373,"completion":1373,"start":1722,"enrollment":1748,"conditions":1749,"interventions":1750},"NCT00881855","To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fed Conditions",[49],35,[18],[1726,1712],{"trials":1752,"activeCount":60},[],{"trials":1754,"activeCount":60},[],{"trials":1756,"activeCount":60},[],{"trials":1758,"activeCount":60},[],{"intervention":1760,"totalTrials":119,"cells":1761},"Eplerenone 50 mg Tablets Sandoz Inc., USA",{"EARLY_PHASE1":1762,"PHASE1":1764,"PHASE2":1782,"PHASE3":1784,"PHASE4":1786,"NA":1788},{"trials":1763,"activeCount":60},[],{"trials":1765,"activeCount":60},[1766,1776],{"nctId":1767,"briefTitle":1768,"status":141,"phases":1769,"primaryCompletion":1770,"completion":1770,"start":1771,"enrollment":1772,"conditions":1773,"interventions":1774},"NCT00865618","Comparative Bioavailability Study of Eplerenone 50 mg Tablets Under Fed Conditions",[49],"2006-07","2006-06",60,[24],[1760,1775],"Inspra 50 mg Tablets GD Searle LLC, USA",{"nctId":1777,"briefTitle":1778,"status":141,"phases":1779,"primaryCompletion":1770,"completion":1770,"start":1771,"enrollment":1772,"conditions":1780,"interventions":1781},"NCT00865176","Comparative Bioavailability Study of Eplerenone 50 mg Tablets Under Fasting Conditions",[49],[24],[1760,1775],{"trials":1783,"activeCount":60},[],{"trials":1785,"activeCount":60},[],{"trials":1787,"activeCount":60},[],{"trials":1789,"activeCount":60},[],{"intervention":1775,"totalTrials":119,"cells":1791},{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1804,"PHASE3":1806,"PHASE4":1808,"NA":1810},{"trials":1793,"activeCount":60},[],{"trials":1795,"activeCount":60},[1796,1800],{"nctId":1767,"briefTitle":1768,"status":141,"phases":1797,"primaryCompletion":1770,"completion":1770,"start":1771,"enrollment":1772,"conditions":1798,"interventions":1799},[49],[24],[1760,1775],{"nctId":1777,"briefTitle":1778,"status":141,"phases":1801,"primaryCompletion":1770,"completion":1770,"start":1771,"enrollment":1772,"conditions":1802,"interventions":1803},[49],[24],[1760,1775],{"trials":1805,"activeCount":60},[],{"trials":1807,"activeCount":60},[],{"trials":1809,"activeCount":60},[],{"trials":1811,"activeCount":60},[],{"intervention":1813,"totalTrials":119,"cells":1814},"Cetirizine HCl\u002FPseudoephedrine HCl 5 mg\u002F120 mg",{"EARLY_PHASE1":1815,"PHASE1":1817,"PHASE2":1835,"PHASE3":1837,"PHASE4":1839,"NA":1841},{"trials":1816,"activeCount":60},[],{"trials":1818,"activeCount":60},[1819,1829],{"nctId":1820,"briefTitle":1821,"status":141,"phases":1822,"primaryCompletion":1328,"completion":1328,"start":1823,"enrollment":1824,"conditions":1825,"interventions":1827},"NCT00881634","To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride\u002FPseudoephedrine Hydrochloride 5 mg\u002F120 mg Extended Release (ER) Tablets Under Fed Conditions",[49],"2005-06",40,[1826],"Allergies",[1813,1828],"Zyrtec-D 12 Hour 5 mg\u002F120 mg Extended Release",{"nctId":1830,"briefTitle":1831,"status":141,"phases":1832,"primaryCompletion":1328,"completion":1328,"start":1328,"enrollment":1824,"conditions":1833,"interventions":1834},"NCT00881127","To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride\u002FPseudoephedrine Hydrochloride 5 mg\u002F120 mg Extended Release (ER) Tablets Under Fasting Conditions",[49],[1826],[1813,1828],{"trials":1836,"activeCount":60},[],{"trials":1838,"activeCount":60},[],{"trials":1840,"activeCount":60},[],{"trials":1842,"activeCount":60},[],{"intervention":1828,"totalTrials":119,"cells":1844},{"EARLY_PHASE1":1845,"PHASE1":1847,"PHASE2":1857,"PHASE3":1859,"PHASE4":1861,"NA":1863},{"trials":1846,"activeCount":60},[],{"trials":1848,"activeCount":60},[1849,1853],{"nctId":1820,"briefTitle":1821,"status":141,"phases":1850,"primaryCompletion":1328,"completion":1328,"start":1823,"enrollment":1824,"conditions":1851,"interventions":1852},[49],[1826],[1813,1828],{"nctId":1830,"briefTitle":1831,"status":141,"phases":1854,"primaryCompletion":1328,"completion":1328,"start":1328,"enrollment":1824,"conditions":1855,"interventions":1856},[49],[1826],[1813,1828],{"trials":1858,"activeCount":60},[],{"trials":1860,"activeCount":60},[],{"trials":1862,"activeCount":60},[],{"trials":1864,"activeCount":60},[],{"intervention":1866,"totalTrials":119,"cells":1867},"Clarithromycin 250 mg",{"EARLY_PHASE1":1868,"PHASE1":1870,"PHASE2":1890,"PHASE3":1892,"PHASE4":1894,"NA":1896},{"trials":1869,"activeCount":60},[],{"trials":1871,"activeCount":60},[1872,1882],{"nctId":1873,"briefTitle":1874,"status":141,"phases":1875,"primaryCompletion":1876,"completion":1877,"start":1876,"enrollment":1878,"conditions":1879,"interventions":1880},"NCT00881738","To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Fasting Conditions",[49],"2002-06","2002-07",32,[18],[1866,1881],"Biaxin 250 mg",{"nctId":1883,"briefTitle":1884,"status":141,"phases":1885,"primaryCompletion":1876,"completion":1876,"start":1886,"enrollment":1741,"conditions":1887,"interventions":1888},"NCT00881179","To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Non-Fasting Conditions",[49],"2002-05",[18],[1866,1889],"Biaxin",{"trials":1891,"activeCount":60},[],{"trials":1893,"activeCount":60},[],{"trials":1895,"activeCount":60},[],{"trials":1897,"activeCount":60},[],{"intervention":1726,"totalTrials":119,"cells":1899},{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1912,"PHASE3":1914,"PHASE4":1916,"NA":1918},{"trials":1901,"activeCount":60},[],{"trials":1903,"activeCount":60},[1904,1908],{"nctId":1719,"briefTitle":1720,"status":141,"phases":1905,"primaryCompletion":1373,"completion":1373,"start":1722,"enrollment":1723,"conditions":1906,"interventions":1907},[49],[18],[1726,1712],{"nctId":1745,"briefTitle":1746,"status":141,"phases":1909,"primaryCompletion":1373,"completion":1373,"start":1722,"enrollment":1748,"conditions":1910,"interventions":1911},[49],[18],[1726,1712],{"trials":1913,"activeCount":60},[],{"trials":1915,"activeCount":60},[],{"trials":1917,"activeCount":60},[],{"trials":1919,"activeCount":60},[],{"intervention":1921,"totalTrials":119,"cells":1922},"Sevirumab",{"EARLY_PHASE1":1923,"PHASE1":1925,"PHASE2":1941,"PHASE3":1943,"PHASE4":1945,"NA":1947},{"trials":1924,"activeCount":60},[],{"trials":1926,"activeCount":60},[1927,1934],{"nctId":1928,"briefTitle":1929,"status":141,"phases":1930,"conditions":1931,"interventions":1933},"NCT00002016","A Phase I\u002FII Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis",[49],[1932,21],"Cytomegalovirus Retinitis",[1921],{"nctId":1935,"briefTitle":1936,"status":141,"phases":1937,"conditions":1938,"interventions":1940},"NCT00002268","A Randomized, Phase I\u002FII Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and\u002For Viruria",[49],[1939,21],"Cytomegalovirus Infections",[1921],{"trials":1942,"activeCount":60},[],{"trials":1944,"activeCount":60},[],{"trials":1946,"activeCount":60},[],{"trials":1948,"activeCount":60},[],{"intervention":1950,"totalTrials":119,"cells":1951},"Bicalutamide 50 mg Film-Coated",{"EARLY_PHASE1":1952,"PHASE1":1954,"PHASE2":1971,"PHASE3":1973,"PHASE4":1975,"NA":1977},{"trials":1953,"activeCount":60},[],{"trials":1955,"activeCount":60},[1956,1965],{"nctId":1957,"briefTitle":1958,"status":141,"phases":1959,"primaryCompletion":1960,"completion":1960,"start":1960,"enrollment":9,"conditions":1961,"interventions":1964},"NCT00959335","Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions",[49],"2006-08",[1962,1963],"Prostate Cancer","Hirsutism",[1950,1950],{"nctId":1966,"briefTitle":1967,"status":141,"phases":1968,"primaryCompletion":1771,"completion":1771,"start":1771,"enrollment":9,"conditions":1969,"interventions":1970},"NCT00960310","Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions",[49],[1962,1963],[1950,1950],{"trials":1972,"activeCount":60},[],{"trials":1974,"activeCount":60},[],{"trials":1976,"activeCount":60},[],{"trials":1978,"activeCount":60},[],{"intervention":1980,"totalTrials":119,"cells":1981},"Divalproex Sodium 500 mg DR",{"EARLY_PHASE1":1982,"PHASE1":1984,"PHASE2":2002,"PHASE3":2004,"PHASE4":2006,"NA":2008},{"trials":1983,"activeCount":60},[],{"trials":1985,"activeCount":60},[1986,1996],{"nctId":1987,"briefTitle":1988,"status":141,"phases":1989,"primaryCompletion":1990,"completion":1990,"start":1990,"enrollment":463,"conditions":1991,"interventions":1994},"NCT00913874","To Demonstrate the Relative Bioavailability of Divalproex Sodium 500 mg Delayed Release Tablets Under Fasting Conditions",[49],"2005-10",[1992,1993],"Epilepsy","Bipolar Disorder",[1980,1995],"Depakote 500 mg DR",{"nctId":1997,"briefTitle":1998,"status":141,"phases":1999,"primaryCompletion":1990,"completion":1990,"start":1990,"enrollment":463,"conditions":2000,"interventions":2001},"NCT00913848","To Demonstrate the Relative Bioavailability of Divalproex Sodium 500 mg Delayed Release Tablets Under Fed Conditions",[49],[1992,1993],[1980,1995],{"trials":2003,"activeCount":60},[],{"trials":2005,"activeCount":60},[],{"trials":2007,"activeCount":60},[],{"trials":2009,"activeCount":60},[],{"intervention":1995,"totalTrials":119,"cells":2011},{"EARLY_PHASE1":2012,"PHASE1":2014,"PHASE2":2024,"PHASE3":2026,"PHASE4":2028,"NA":2030},{"trials":2013,"activeCount":60},[],{"trials":2015,"activeCount":60},[2016,2020],{"nctId":1987,"briefTitle":1988,"status":141,"phases":2017,"primaryCompletion":1990,"completion":1990,"start":1990,"enrollment":463,"conditions":2018,"interventions":2019},[49],[1992,1993],[1980,1995],{"nctId":1997,"briefTitle":1998,"status":141,"phases":2021,"primaryCompletion":1990,"completion":1990,"start":1990,"enrollment":463,"conditions":2022,"interventions":2023},[49],[1992,1993],[1980,1995],{"trials":2025,"activeCount":60},[],{"trials":2027,"activeCount":60},[],{"trials":2029,"activeCount":60},[],{"trials":2031,"activeCount":60},[],{"intervention":2033,"totalTrials":119,"cells":2034},"Altace",{"EARLY_PHASE1":2035,"PHASE1":2037,"PHASE2":2055,"PHASE3":2057,"PHASE4":2059,"NA":2061},{"trials":2036,"activeCount":60},[],{"trials":2038,"activeCount":60},[2039,2048],{"nctId":2040,"briefTitle":2041,"status":141,"phases":2042,"primaryCompletion":1330,"completion":1330,"start":2043,"enrollment":2044,"conditions":2045,"interventions":2046},"NCT00946465","To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions",[49],"2004-10",48,[24],[2047,2033],"Ramipril 10",{"nctId":2049,"briefTitle":2050,"status":141,"phases":2051,"primaryCompletion":1330,"completion":1330,"start":2043,"enrollment":2044,"conditions":2052,"interventions":2053},"NCT00946621","To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Non-Fasting Conditions",[49],[24],[2054,2033],"Ramipril 10 mg",{"trials":2056,"activeCount":60},[],{"trials":2058,"activeCount":60},[],{"trials":2060,"activeCount":60},[],{"trials":2062,"activeCount":60},[],{"intervention":2064,"totalTrials":119,"cells":2065},"Ondansetron HCl 24 mg",{"EARLY_PHASE1":2066,"PHASE1":2068,"PHASE2":2086,"PHASE3":2088,"PHASE4":2090,"NA":2092},{"trials":2067,"activeCount":60},[],{"trials":2069,"activeCount":60},[2070,2080],{"nctId":2071,"briefTitle":2072,"status":141,"phases":2073,"primaryCompletion":2043,"completion":2043,"start":2074,"enrollment":1723,"conditions":2075,"interventions":2078},"NCT00947128","To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions",[49],"2004-09",[2076,2077],"Nausea","Vomiting",[2064,2079],"Zofran",{"nctId":2081,"briefTitle":2082,"status":141,"phases":2083,"primaryCompletion":2074,"completion":2074,"start":2074,"enrollment":1723,"conditions":2084,"interventions":2085},"NCT00946387","To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions",[49],[2076,2077],[2064,2079],{"trials":2087,"activeCount":60},[],{"trials":2089,"activeCount":60},[],{"trials":2091,"activeCount":60},[],{"trials":2093,"activeCount":60},[],{"intervention":2079,"totalTrials":119,"cells":2095},{"EARLY_PHASE1":2096,"PHASE1":2098,"PHASE2":2108,"PHASE3":2110,"PHASE4":2112,"NA":2114},{"trials":2097,"activeCount":60},[],{"trials":2099,"activeCount":60},[2100,2104],{"nctId":2071,"briefTitle":2072,"status":141,"phases":2101,"primaryCompletion":2043,"completion":2043,"start":2074,"enrollment":1723,"conditions":2102,"interventions":2103},[49],[2076,2077],[2064,2079],{"nctId":2081,"briefTitle":2082,"status":141,"phases":2105,"primaryCompletion":2074,"completion":2074,"start":2074,"enrollment":1723,"conditions":2106,"interventions":2107},[49],[2076,2077],[2064,2079],{"trials":2109,"activeCount":60},[],{"trials":2111,"activeCount":60},[],{"trials":2113,"activeCount":60},[],{"trials":2115,"activeCount":60},[],{"intervention":1736,"totalTrials":119,"cells":2117},{"EARLY_PHASE1":2118,"PHASE1":2120,"PHASE2":2130,"PHASE3":2132,"PHASE4":2134,"NA":2136},{"trials":2119,"activeCount":60},[],{"trials":2121,"activeCount":60},[2122,2126],{"nctId":1728,"briefTitle":1729,"status":141,"phases":2123,"primaryCompletion":1731,"completion":1731,"start":1732,"enrollment":1733,"conditions":2124,"interventions":2125},[49],[18],[1736,1712],{"nctId":1738,"briefTitle":1739,"status":141,"phases":2127,"primaryCompletion":1731,"completion":1731,"start":1731,"enrollment":1741,"conditions":2128,"interventions":2129},[49],[18],[1736,1712],{"trials":2131,"activeCount":60},[],{"trials":2133,"activeCount":60},[],{"trials":2135,"activeCount":60},[],{"trials":2137,"activeCount":60},[],{"intervention":2139,"totalTrials":119,"cells":2140},"Cefdinir 300 mg",{"EARLY_PHASE1":2141,"PHASE1":2143,"PHASE2":2159,"PHASE3":2161,"PHASE4":2163,"NA":2165},{"trials":2142,"activeCount":60},[],{"trials":2144,"activeCount":60},[2145,2153],{"nctId":2146,"briefTitle":2147,"status":141,"phases":2148,"primaryCompletion":2149,"completion":2149,"start":2149,"enrollment":1304,"conditions":2150,"interventions":2151},"NCT00882154","To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 300 mg Capsule Fed Conditions",[49],"2005-04",[18],[2139,2152],"Omnicef Cefdinir 300 mg",{"nctId":2154,"briefTitle":2155,"status":141,"phases":2156,"primaryCompletion":2149,"completion":2149,"start":2149,"enrollment":1304,"conditions":2157,"interventions":2158},"NCT00882700","To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicef 300 mg Capsule Fasting Conditions",[49],[18],[2139,2152],{"trials":2160,"activeCount":60},[],{"trials":2162,"activeCount":60},[],{"trials":2164,"activeCount":60},[],{"trials":2166,"activeCount":60},[],{"intervention":2152,"totalTrials":119,"cells":2168},{"EARLY_PHASE1":2169,"PHASE1":2171,"PHASE2":2181,"PHASE3":2183,"PHASE4":2185,"NA":2187},{"trials":2170,"activeCount":60},[],{"trials":2172,"activeCount":60},[2173,2177],{"nctId":2146,"briefTitle":2147,"status":141,"phases":2174,"primaryCompletion":2149,"completion":2149,"start":2149,"enrollment":1304,"conditions":2175,"interventions":2176},[49],[18],[2139,2152],{"nctId":2154,"briefTitle":2155,"status":141,"phases":2178,"primaryCompletion":2149,"completion":2149,"start":2149,"enrollment":1304,"conditions":2179,"interventions":2180},[49],[18],[2139,2152],{"trials":2182,"activeCount":60},[],{"trials":2184,"activeCount":60},[],{"trials":2186,"activeCount":60},[],{"trials":2188,"activeCount":60},[],{"intervention":2190,"totalTrials":56,"cells":2191},"Fluoxetine HCl 20 mg Capsules Under Fasting Conditions",{"EARLY_PHASE1":2192,"PHASE1":2194,"PHASE2":2206,"PHASE3":2208,"PHASE4":2210,"NA":2212},{"trials":2193,"activeCount":60},[],{"trials":2195,"activeCount":60},[2196],{"nctId":2197,"briefTitle":2198,"status":141,"phases":2199,"primaryCompletion":2200,"completion":2200,"start":2201,"enrollment":1741,"conditions":2202,"interventions":2203},"NCT00913588","To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fed and Fasted Conditions",[49],"1996-08","1996-05",[15],[2190,2204,2205],"Fluoxetine HCl 20 mg Capsules Under Fed Conditions","Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions",{"trials":2207,"activeCount":60},[],{"trials":2209,"activeCount":60},[],{"trials":2211,"activeCount":60},[],{"trials":2213,"activeCount":60},[],{"intervention":2204,"totalTrials":56,"cells":2215},{"EARLY_PHASE1":2216,"PHASE1":2218,"PHASE2":2224,"PHASE3":2226,"PHASE4":2228,"NA":2230},{"trials":2217,"activeCount":60},[],{"trials":2219,"activeCount":60},[2220],{"nctId":2197,"briefTitle":2198,"status":141,"phases":2221,"primaryCompletion":2200,"completion":2200,"start":2201,"enrollment":1741,"conditions":2222,"interventions":2223},[49],[15],[2190,2204,2205],{"trials":2225,"activeCount":60},[],{"trials":2227,"activeCount":60},[],{"trials":2229,"activeCount":60},[],{"trials":2231,"activeCount":60},[],{"intervention":2205,"totalTrials":56,"cells":2233},{"EARLY_PHASE1":2234,"PHASE1":2236,"PHASE2":2242,"PHASE3":2244,"PHASE4":2246,"NA":2248},{"trials":2235,"activeCount":60},[],{"trials":2237,"activeCount":60},[2238],{"nctId":2197,"briefTitle":2198,"status":141,"phases":2239,"primaryCompletion":2200,"completion":2200,"start":2201,"enrollment":1741,"conditions":2240,"interventions":2241},[49],[15],[2190,2204,2205],{"trials":2243,"activeCount":60},[],{"trials":2245,"activeCount":60},[],{"trials":2247,"activeCount":60},[],{"trials":2249,"activeCount":60},[],{"intervention":2251,"totalTrials":56,"cells":2252},"Cefdinir 250 mg\u002F5 ml Suspension",{"EARLY_PHASE1":2253,"PHASE1":2255,"PHASE2":2265,"PHASE3":2267,"PHASE4":2269,"NA":2271},{"trials":2254,"activeCount":60},[],{"trials":2256,"activeCount":60},[2257],{"nctId":2258,"briefTitle":2259,"status":141,"phases":2260,"primaryCompletion":2261,"completion":2261,"start":2149,"enrollment":1824,"conditions":2262,"interventions":2263},"NCT00883883","To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250 mg\u002F5 ml Oral Suspension Fed Conditions",[49],"2005-05",[18],[2251,2264],"Omnicef Cefdinir 250 mg\u002F5 ml Suspension",{"trials":2266,"activeCount":60},[],{"trials":2268,"activeCount":60},[],{"trials":2270,"activeCount":60},[],{"trials":2272,"activeCount":60},[],{"intervention":2264,"totalTrials":56,"cells":2274},{"EARLY_PHASE1":2275,"PHASE1":2277,"PHASE2":2283,"PHASE3":2285,"PHASE4":2287,"NA":2289},{"trials":2276,"activeCount":60},[],{"trials":2278,"activeCount":60},[2279],{"nctId":2258,"briefTitle":2259,"status":141,"phases":2280,"primaryCompletion":2261,"completion":2261,"start":2149,"enrollment":1824,"conditions":2281,"interventions":2282},[49],[18],[2251,2264],{"trials":2284,"activeCount":60},[],{"trials":2286,"activeCount":60},[],{"trials":2288,"activeCount":60},[],{"trials":2290,"activeCount":60},[],{"intervention":2292,"totalTrials":56,"cells":2293},"Olaparib tablets, 150 mg",{"EARLY_PHASE1":2294,"PHASE1":2296,"PHASE2":2309,"PHASE3":2311,"PHASE4":2313,"NA":2315},{"trials":2295,"activeCount":60},[],{"trials":2297,"activeCount":60},[2298],{"nctId":2299,"briefTitle":2300,"status":141,"phases":2301,"primaryCompletion":2302,"completion":2302,"start":2303,"enrollment":2304,"conditions":2305,"interventions":2307},"NCT05258747","A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer",[49],"2022-10-20","2022-04-07",70,[2306,34],"Ovarian Cancer",[2292,2308],"Lynparza® (olaparib) tablets 150 mg",{"trials":2310,"activeCount":60},[],{"trials":2312,"activeCount":60},[],{"trials":2314,"activeCount":60},[],{"trials":2316,"activeCount":60},[],{"intervention":2308,"totalTrials":56,"cells":2318},{"EARLY_PHASE1":2319,"PHASE1":2321,"PHASE2":2327,"PHASE3":2329,"PHASE4":2331,"NA":2333},{"trials":2320,"activeCount":60},[],{"trials":2322,"activeCount":60},[2323],{"nctId":2299,"briefTitle":2300,"status":141,"phases":2324,"primaryCompletion":2302,"completion":2302,"start":2303,"enrollment":2304,"conditions":2325,"interventions":2326},[49],[2306,34],[2292,2308],{"trials":2328,"activeCount":60},[],{"trials":2330,"activeCount":60},[],{"trials":2332,"activeCount":60},[],{"trials":2334,"activeCount":60},[],{"intervention":2336,"totalTrials":56,"cells":2337},"Naproxen Delayed Release Tables, 375",{"EARLY_PHASE1":2338,"PHASE1":2340,"PHASE2":2352,"PHASE3":2354,"PHASE4":2356,"NA":2358},{"trials":2339,"activeCount":60},[],{"trials":2341,"activeCount":60},[2342],{"nctId":2343,"briefTitle":2344,"status":141,"phases":2345,"primaryCompletion":1886,"completion":1886,"start":2346,"enrollment":2347,"conditions":2348,"interventions":2350},"NCT00959439","Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)",[49],"2002-03",34,[29,2349],"Osteoarthritis",[2336,2351],"Naproxen",{"trials":2353,"activeCount":60},[],{"trials":2355,"activeCount":60},[],{"trials":2357,"activeCount":60},[],{"trials":2359,"activeCount":60},[],{"intervention":2351,"totalTrials":56,"cells":2361},{"EARLY_PHASE1":2362,"PHASE1":2364,"PHASE2":2370,"PHASE3":2372,"PHASE4":2374,"NA":2376},{"trials":2363,"activeCount":60},[],{"trials":2365,"activeCount":60},[2366],{"nctId":2343,"briefTitle":2344,"status":141,"phases":2367,"primaryCompletion":1886,"completion":1886,"start":2346,"enrollment":2347,"conditions":2368,"interventions":2369},[49],[29,2349],[2336,2351],{"trials":2371,"activeCount":60},[],{"trials":2373,"activeCount":60},[],{"trials":2375,"activeCount":60},[],{"trials":2377,"activeCount":60},[],{"intervention":2379,"totalTrials":56,"cells":2380},"Fentanyl patch 25 ug\u002Fnr Sandoz",{"EARLY_PHASE1":2381,"PHASE1":2383,"PHASE2":2395,"PHASE3":2397,"PHASE4":2399,"NA":2401},{"trials":2382,"activeCount":60},[],{"trials":2384,"activeCount":60},[2385],{"nctId":2386,"briefTitle":2387,"status":141,"phases":2388,"primaryCompletion":2389,"completion":2389,"start":2390,"enrollment":1824,"conditions":2391,"interventions":2393},"NCT00857753","Relative Bioavailability of a Fentanyl Patch",[49],"2006-10","2006-09",[2392],"Pain",[2379,2394],"Duragesic",{"trials":2396,"activeCount":60},[],{"trials":2398,"activeCount":60},[],{"trials":2400,"activeCount":60},[],{"trials":2402,"activeCount":60},[],{"intervention":2394,"totalTrials":56,"cells":2404},{"EARLY_PHASE1":2405,"PHASE1":2407,"PHASE2":2413,"PHASE3":2415,"PHASE4":2417,"NA":2419},{"trials":2406,"activeCount":60},[],{"trials":2408,"activeCount":60},[2409],{"nctId":2386,"briefTitle":2387,"status":141,"phases":2410,"primaryCompletion":2389,"completion":2389,"start":2390,"enrollment":1824,"conditions":2411,"interventions":2412},[49],[2392],[2379,2394],{"trials":2414,"activeCount":60},[],{"trials":2416,"activeCount":60},[],{"trials":2418,"activeCount":60},[],{"trials":2420,"activeCount":60},[],{"intervention":2422,"totalTrials":56,"cells":2423},"Cilostazol 50 mg",{"EARLY_PHASE1":2424,"PHASE1":2426,"PHASE2":2437,"PHASE3":2439,"PHASE4":2441,"NA":2443},{"trials":2425,"activeCount":60},[],{"trials":2427,"activeCount":60},[2428],{"nctId":2429,"briefTitle":2430,"status":141,"phases":2431,"primaryCompletion":2432,"completion":2432,"start":2433,"enrollment":1723,"conditions":2434,"interventions":2435},"NCT00881231","To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions",[49],"2004-02","2004-01",[2392],[2422,2436],"Pletal",{"trials":2438,"activeCount":60},[],{"trials":2440,"activeCount":60},[],{"trials":2442,"activeCount":60},[],{"trials":2444,"activeCount":60},[],{"intervention":2436,"totalTrials":56,"cells":2446},{"EARLY_PHASE1":2447,"PHASE1":2449,"PHASE2":2455,"PHASE3":2457,"PHASE4":2459,"NA":2461},{"trials":2448,"activeCount":60},[],{"trials":2450,"activeCount":60},[2451],{"nctId":2429,"briefTitle":2430,"status":141,"phases":2452,"primaryCompletion":2432,"completion":2432,"start":2433,"enrollment":1723,"conditions":2453,"interventions":2454},[49],[2392],[2422,2436],{"trials":2456,"activeCount":60},[],{"trials":2458,"activeCount":60},[],{"trials":2460,"activeCount":60},[],{"trials":2462,"activeCount":60},[],{"intervention":2464,"totalTrials":56,"cells":2465},"Desipramine HCl 50 mg Tablets Cord Laboratories",{"EARLY_PHASE1":2466,"PHASE1":2468,"PHASE2":2477,"PHASE3":2479,"PHASE4":2481,"NA":2483},{"trials":2467,"activeCount":60},[],{"trials":2469,"activeCount":60},[2470],{"nctId":2471,"briefTitle":2472,"status":141,"phases":2473,"enrollment":9,"conditions":2474,"interventions":2475},"NCT00914004","To Demonstrate the Relative Bioequivalency of Comparing Single 100 mg Doses Of Cord's 50 mg Desipramine HCL Tablets To Merrell Dow's 50 mg Norpramin Tablets",[49],[15],[2464,2476],"Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc",{"trials":2478,"activeCount":60},[],{"trials":2480,"activeCount":60},[],{"trials":2482,"activeCount":60},[],{"trials":2484,"activeCount":60},[],{"intervention":2476,"totalTrials":56,"cells":2486},{"EARLY_PHASE1":2487,"PHASE1":2489,"PHASE2":2495,"PHASE3":2497,"PHASE4":2499,"NA":2501},{"trials":2488,"activeCount":60},[],{"trials":2490,"activeCount":60},[2491],{"nctId":2471,"briefTitle":2472,"status":141,"phases":2492,"enrollment":9,"conditions":2493,"interventions":2494},[49],[15],[2464,2476],{"trials":2496,"activeCount":60},[],{"trials":2498,"activeCount":60},[],{"trials":2500,"activeCount":60},[],{"trials":2502,"activeCount":60},[],{"intervention":2504,"totalTrials":56,"cells":2505},"Desipramine Hydrochloride 50 mg",{"EARLY_PHASE1":2506,"PHASE1":2508,"PHASE2":2518,"PHASE3":2520,"PHASE4":2522,"NA":2524},{"trials":2507,"activeCount":60},[],{"trials":2509,"activeCount":60},[2510],{"nctId":2511,"briefTitle":2512,"status":141,"phases":2513,"primaryCompletion":2514,"completion":2514,"start":2515,"enrollment":9,"conditions":2516,"interventions":2517},"NCT00913237","To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride 50 mg Tablets",[49],"1987-08","1987-07",[15],[2504,2504],{"trials":2519,"activeCount":60},[],{"trials":2521,"activeCount":60},[],{"trials":2523,"activeCount":60},[],{"trials":2525,"activeCount":60},[],{"intervention":2527,"totalTrials":56,"cells":2528},"Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC",{"EARLY_PHASE1":2529,"PHASE1":2531,"PHASE2":2543,"PHASE3":2545,"PHASE4":2547,"NA":2549},{"trials":2530,"activeCount":60},[],{"trials":2532,"activeCount":60},[2533],{"nctId":2534,"briefTitle":2535,"status":141,"phases":2536,"primaryCompletion":2537,"completion":2537,"start":2537,"enrollment":2538,"conditions":2539,"interventions":2541},"NCT00882882","To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions",[49],"2001-06",16,[2540],"Type II Diabetes",[2527,2527,2542,2542],"GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb",{"trials":2544,"activeCount":60},[],{"trials":2546,"activeCount":60},[],{"trials":2548,"activeCount":60},[],{"trials":2550,"activeCount":60},[],{"intervention":2542,"totalTrials":56,"cells":2552},{"EARLY_PHASE1":2553,"PHASE1":2555,"PHASE2":2561,"PHASE3":2563,"PHASE4":2565,"NA":2567},{"trials":2554,"activeCount":60},[],{"trials":2556,"activeCount":60},[2557],{"nctId":2534,"briefTitle":2535,"status":141,"phases":2558,"primaryCompletion":2537,"completion":2537,"start":2537,"enrollment":2538,"conditions":2559,"interventions":2560},[49],[2540],[2527,2527,2542,2542],{"trials":2562,"activeCount":60},[],{"trials":2564,"activeCount":60},[],{"trials":2566,"activeCount":60},[],{"trials":2568,"activeCount":60},[],{"intervention":2570,"totalTrials":56,"cells":2571},"Diclofenac Sodium 50 mg",{"EARLY_PHASE1":2572,"PHASE1":2574,"PHASE2":2586,"PHASE3":2588,"PHASE4":2590,"NA":2592},{"trials":2573,"activeCount":60},[],{"trials":2575,"activeCount":60},[2576],{"nctId":2577,"briefTitle":2578,"status":141,"phases":2579,"primaryCompletion":2580,"completion":2580,"start":2580,"enrollment":2581,"conditions":2582,"interventions":2584},"NCT00913224","To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets",[49],"1993-04",38,[2583],"Inflammation",[2570,2585],"Voltaren 50 mg",{"trials":2587,"activeCount":60},[],{"trials":2589,"activeCount":60},[],{"trials":2591,"activeCount":60},[],{"trials":2593,"activeCount":60},[],{"intervention":2585,"totalTrials":56,"cells":2595},{"EARLY_PHASE1":2596,"PHASE1":2598,"PHASE2":2604,"PHASE3":2606,"PHASE4":2608,"NA":2610},{"trials":2597,"activeCount":60},[],{"trials":2599,"activeCount":60},[2600],{"nctId":2577,"briefTitle":2578,"status":141,"phases":2601,"primaryCompletion":2580,"completion":2580,"start":2580,"enrollment":2581,"conditions":2602,"interventions":2603},[49],[2583],[2570,2585],{"trials":2605,"activeCount":60},[],{"trials":2607,"activeCount":60},[],{"trials":2609,"activeCount":60},[],{"trials":2611,"activeCount":60},[],{"intervention":2613,"totalTrials":56,"cells":2614},"Clomipramine Hydrochloride 25 mg",{"EARLY_PHASE1":2615,"PHASE1":2617,"PHASE2":2628,"PHASE3":2630,"PHASE4":2632,"NA":2634},{"trials":2616,"activeCount":60},[],{"trials":2618,"activeCount":60},[2619],{"nctId":2620,"briefTitle":2621,"status":141,"phases":2622,"primaryCompletion":2623,"completion":2623,"start":2624,"enrollment":9,"conditions":2625,"interventions":2626},"NCT00913783","To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fasted Conditions",[49],"1992-12","1992-11",[15],[2613,2627],"Anafranil Clomipramine Hydrochloride 25 mg",{"trials":2629,"activeCount":60},[],{"trials":2631,"activeCount":60},[],{"trials":2633,"activeCount":60},[],{"trials":2635,"activeCount":60},[],{"intervention":2627,"totalTrials":56,"cells":2637},{"EARLY_PHASE1":2638,"PHASE1":2640,"PHASE2":2646,"PHASE3":2648,"PHASE4":2650,"NA":2652},{"trials":2639,"activeCount":60},[],{"trials":2641,"activeCount":60},[2642],{"nctId":2620,"briefTitle":2621,"status":141,"phases":2643,"primaryCompletion":2623,"completion":2623,"start":2624,"enrollment":9,"conditions":2644,"interventions":2645},[49],[15],[2613,2627],{"trials":2647,"activeCount":60},[],{"trials":2649,"activeCount":60},[],{"trials":2651,"activeCount":60},[],{"trials":2653,"activeCount":60},[],{"intervention":2655,"totalTrials":56,"cells":2656},"Generic Loteprednol Etabonate",{"EARLY_PHASE1":2657,"PHASE1":2659,"PHASE2":2673,"PHASE3":2675,"PHASE4":2677,"NA":2679},{"trials":2658,"activeCount":60},[],{"trials":2660,"activeCount":60},[2661],{"nctId":2662,"briefTitle":2663,"status":141,"phases":2664,"primaryCompletion":2665,"completion":2666,"start":2667,"enrollment":2668,"conditions":2669,"interventions":2671},"NCT03531697","Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery",[49],"2019-09-07","2019-10-07","2018-04-26",381,[2670],"Inflammation Following Ocular Surgery",[2655,2672],"Reference Listed Drug",{"trials":2674,"activeCount":60},[],{"trials":2676,"activeCount":60},[],{"trials":2678,"activeCount":60},[],{"trials":2680,"activeCount":60},[],{"intervention":2672,"totalTrials":56,"cells":2682},{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2691,"PHASE3":2693,"PHASE4":2695,"NA":2697},{"trials":2684,"activeCount":60},[],{"trials":2686,"activeCount":60},[2687],{"nctId":2662,"briefTitle":2663,"status":141,"phases":2688,"primaryCompletion":2665,"completion":2666,"start":2667,"enrollment":2668,"conditions":2689,"interventions":2690},[49],[2670],[2655,2672],{"trials":2692,"activeCount":60},[],{"trials":2694,"activeCount":60},[],{"trials":2696,"activeCount":60},[],{"trials":2698,"activeCount":60},[],{"intervention":1881,"totalTrials":56,"cells":2700},{"EARLY_PHASE1":2701,"PHASE1":2703,"PHASE2":2709,"PHASE3":2711,"PHASE4":2713,"NA":2715},{"trials":2702,"activeCount":60},[],{"trials":2704,"activeCount":60},[2705],{"nctId":1873,"briefTitle":1874,"status":141,"phases":2706,"primaryCompletion":1876,"completion":1877,"start":1876,"enrollment":1878,"conditions":2707,"interventions":2708},[49],[18],[1866,1881],{"trials":2710,"activeCount":60},[],{"trials":2712,"activeCount":60},[],{"trials":2714,"activeCount":60},[],{"trials":2716,"activeCount":60},[],{"intervention":2718,"totalTrials":56,"cells":2719},"Hydroxychloroquine Sulfate Tablets, 200 mg",{"EARLY_PHASE1":2720,"PHASE1":2722,"PHASE2":2736,"PHASE3":2738,"PHASE4":2740,"NA":2742},{"trials":2721,"activeCount":60},[],{"trials":2723,"activeCount":60},[2724],{"nctId":2725,"briefTitle":2726,"status":141,"phases":2727,"primaryCompletion":2728,"completion":2728,"start":2729,"enrollment":2730,"conditions":2731,"interventions":2734},"NCT00946790","To Demonstrate the Relative Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets",[49],"1993-12","1993-07",72,[2732,2733],"Immunosuppression","Rheumatism",[2718,2735],"Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil",{"trials":2737,"activeCount":60},[],{"trials":2739,"activeCount":60},[],{"trials":2741,"activeCount":60},[],{"trials":2743,"activeCount":60},[],{"intervention":2735,"totalTrials":56,"cells":2745},{"EARLY_PHASE1":2746,"PHASE1":2748,"PHASE2":2754,"PHASE3":2756,"PHASE4":2758,"NA":2760},{"trials":2747,"activeCount":60},[],{"trials":2749,"activeCount":60},[2750],{"nctId":2725,"briefTitle":2726,"status":141,"phases":2751,"primaryCompletion":2728,"completion":2728,"start":2729,"enrollment":2730,"conditions":2752,"interventions":2753},[49],[2732,2733],[2718,2735],{"trials":2755,"activeCount":60},[],{"trials":2757,"activeCount":60},[],{"trials":2759,"activeCount":60},[],{"trials":2761,"activeCount":60},[],{"intervention":2763,"totalTrials":56,"cells":2764},"Atenolol Tablets 100 mg",{"EARLY_PHASE1":2765,"PHASE1":2767,"PHASE2":2777,"PHASE3":2779,"PHASE4":2781,"NA":2783},{"trials":2766,"activeCount":60},[],{"trials":2768,"activeCount":60},[2769],{"nctId":2770,"briefTitle":2771,"status":141,"phases":2772,"primaryCompletion":2773,"completion":2773,"start":2774,"enrollment":1741,"conditions":2775,"interventions":2776},"NCT00913965","To Demonstrate the Relative Bioavailability of Atenolol Tablets",[49],"1989-08","1989-07",[24],[2763,2763],{"trials":2778,"activeCount":60},[],{"trials":2780,"activeCount":60},[],{"trials":2782,"activeCount":60},[],{"trials":2784,"activeCount":60},[],{"intervention":2786,"totalTrials":56,"cells":2787},"Fluoxetine Hydrochloride 20 mg",{"EARLY_PHASE1":2788,"PHASE1":2790,"PHASE2":2802,"PHASE3":2804,"PHASE4":2806,"NA":2808},{"trials":2789,"activeCount":60},[],{"trials":2791,"activeCount":60},[2792],{"nctId":2793,"briefTitle":2794,"status":141,"phases":2795,"primaryCompletion":2796,"completion":2796,"start":2797,"enrollment":2798,"conditions":2799,"interventions":2800},"NCT00913718","To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fasting Conditions",[49],"1996-07","1996-06",46,[15],[2786,2801],"Prozac Fluoxetine Hydrochloride 20 mg",{"trials":2803,"activeCount":60},[],{"trials":2805,"activeCount":60},[],{"trials":2807,"activeCount":60},[],{"trials":2809,"activeCount":60},[],{"intervention":2801,"totalTrials":56,"cells":2811},{"EARLY_PHASE1":2812,"PHASE1":2814,"PHASE2":2820,"PHASE3":2822,"PHASE4":2824,"NA":2826},{"trials":2813,"activeCount":60},[],{"trials":2815,"activeCount":60},[2816],{"nctId":2793,"briefTitle":2794,"status":141,"phases":2817,"primaryCompletion":2796,"completion":2796,"start":2797,"enrollment":2798,"conditions":2818,"interventions":2819},[49],[15],[2786,2801],{"trials":2821,"activeCount":60},[],{"trials":2823,"activeCount":60},[],{"trials":2825,"activeCount":60},[],{"trials":2827,"activeCount":60},[],{"intervention":2829,"totalTrials":56,"cells":2830},"Loratadine 10 mg Tablets Under Fasting Conditions",{"EARLY_PHASE1":2831,"PHASE1":2833,"PHASE2":2845,"PHASE3":2847,"PHASE4":2849,"NA":2851},{"trials":2832,"activeCount":60},[],{"trials":2834,"activeCount":60},[2835],{"nctId":2836,"briefTitle":2837,"status":141,"phases":2838,"primaryCompletion":2839,"completion":2839,"start":1823,"enrollment":463,"conditions":2840,"interventions":2842},"NCT00946608","To Demonstrate the Relative Bioavailability Study of Loratadine 10 mg Tablets",[49],"2005-08",[2841],"Allergy",[2829,2843,2844],"Loratadine 10 mg Tablets Under Fed Conditions","Claritin",{"trials":2846,"activeCount":60},[],{"trials":2848,"activeCount":60},[],{"trials":2850,"activeCount":60},[],{"trials":2852,"activeCount":60},[],{"intervention":2843,"totalTrials":56,"cells":2854},{"EARLY_PHASE1":2855,"PHASE1":2857,"PHASE2":2863,"PHASE3":2865,"PHASE4":2867,"NA":2869},{"trials":2856,"activeCount":60},[],{"trials":2858,"activeCount":60},[2859],{"nctId":2836,"briefTitle":2837,"status":141,"phases":2860,"primaryCompletion":2839,"completion":2839,"start":1823,"enrollment":463,"conditions":2861,"interventions":2862},[49],[2841],[2829,2843,2844],{"trials":2864,"activeCount":60},[],{"trials":2866,"activeCount":60},[],{"trials":2868,"activeCount":60},[],{"trials":2870,"activeCount":60},[],{"intervention":2844,"totalTrials":56,"cells":2872},{"EARLY_PHASE1":2873,"PHASE1":2875,"PHASE2":2881,"PHASE3":2883,"PHASE4":2885,"NA":2887},{"trials":2874,"activeCount":60},[],{"trials":2876,"activeCount":60},[2877],{"nctId":2836,"briefTitle":2837,"status":141,"phases":2878,"primaryCompletion":2839,"completion":2839,"start":1823,"enrollment":463,"conditions":2879,"interventions":2880},[49],[2841],[2829,2843,2844],{"trials":2882,"activeCount":60},[],{"trials":2884,"activeCount":60},[],{"trials":2886,"activeCount":60},[],{"trials":2888,"activeCount":60},[],{"intervention":2890,"totalTrials":56,"cells":2891},"Desipramine HCL 100 mg Tablets Cord Laboratories",{"EARLY_PHASE1":2892,"PHASE1":2894,"PHASE2":2904,"PHASE3":2906,"PHASE4":2908,"NA":2910},{"trials":2893,"activeCount":60},[],{"trials":2895,"activeCount":60},[2896],{"nctId":2897,"briefTitle":2898,"status":141,"phases":2899,"primaryCompletion":2900,"completion":2900,"start":2900,"enrollment":9,"conditions":2901,"interventions":2902},"NCT00913809","To Demonstrate the Relative Bioequivalency of Cord's 100 mg Desipramine HCL Tablets To Merrell Dow's 100 mg Norpramin Tablets",[49],"1987-12",[15],[2890,2903],"Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc",{"trials":2905,"activeCount":60},[],{"trials":2907,"activeCount":60},[],{"trials":2909,"activeCount":60},[],{"trials":2911,"activeCount":60},[],{"intervention":2903,"totalTrials":56,"cells":2913},{"EARLY_PHASE1":2914,"PHASE1":2916,"PHASE2":2922,"PHASE3":2924,"PHASE4":2926,"NA":2928},{"trials":2915,"activeCount":60},[],{"trials":2917,"activeCount":60},[2918],{"nctId":2897,"briefTitle":2898,"status":141,"phases":2919,"primaryCompletion":2900,"completion":2900,"start":2900,"enrollment":9,"conditions":2920,"interventions":2921},[49],[15],[2890,2903],{"trials":2923,"activeCount":60},[],{"trials":2925,"activeCount":60},[],{"trials":2927,"activeCount":60},[],{"trials":2929,"activeCount":60},[],{"intervention":2931,"totalTrials":56,"cells":2932},"Interleukin-3",{"EARLY_PHASE1":2933,"PHASE1":2935,"PHASE2":2943,"PHASE3":2945,"PHASE4":2947,"NA":2949},{"trials":2934,"activeCount":60},[],{"trials":2936,"activeCount":60},[2937],{"nctId":2938,"briefTitle":2939,"status":141,"phases":2940,"conditions":2941,"interventions":2942},"NCT00002258","A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia",[49],[21,27],[2931],{"trials":2944,"activeCount":60},[],{"trials":2946,"activeCount":60},[],{"trials":2948,"activeCount":60},[],{"trials":2950,"activeCount":60},[],{"intervention":2952,"totalTrials":56,"cells":2953},"Metformin HCL Tablets, 1000 mg Sandoz",{"EARLY_PHASE1":2954,"PHASE1":2956,"PHASE2":2967,"PHASE3":2969,"PHASE4":2971,"NA":2973},{"trials":2955,"activeCount":60},[],{"trials":2957,"activeCount":60},[2958],{"nctId":2959,"briefTitle":2960,"status":141,"phases":2961,"primaryCompletion":2962,"completion":2962,"start":2962,"enrollment":1878,"conditions":2963,"interventions":2965},"NCT00865033","A Relative Bioavailability Study of Metformin HCL Tablets, 1000 mg Under Fasting Conditions",[49],"2005-11",[2964],"Type 2 Diabetes",[2952,2966],"Glucophage 1000 mg",{"trials":2968,"activeCount":60},[],{"trials":2970,"activeCount":60},[],{"trials":2972,"activeCount":60},[],{"trials":2974,"activeCount":60},[],{"intervention":2966,"totalTrials":56,"cells":2976},{"EARLY_PHASE1":2977,"PHASE1":2979,"PHASE2":2985,"PHASE3":2987,"PHASE4":2989,"NA":2991},{"trials":2978,"activeCount":60},[],{"trials":2980,"activeCount":60},[2981],{"nctId":2959,"briefTitle":2960,"status":141,"phases":2982,"primaryCompletion":2962,"completion":2962,"start":2962,"enrollment":1878,"conditions":2983,"interventions":2984},[49],[2964],[2952,2966],{"trials":2986,"activeCount":60},[],{"trials":2988,"activeCount":60},[],{"trials":2990,"activeCount":60},[],{"trials":2992,"activeCount":60},[],{"intervention":2994,"totalTrials":56,"cells":2995},"Mometasone + Azelastine",{"EARLY_PHASE1":2996,"PHASE1":2998,"PHASE2":3010,"PHASE3":3012,"PHASE4":3014,"NA":3016},{"trials":2997,"activeCount":60},[],{"trials":2999,"activeCount":60},[3000],{"nctId":3001,"briefTitle":3002,"status":204,"phases":3003,"primaryCompletion":3004,"completion":3004,"start":3005,"enrollment":2581,"conditions":3006,"interventions":3007},"NCT05887843","Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis",[49],"2023-09-08","2023-06-08",[661],[2994,3008,3009],"Mometasone Furoate","Azelastine Hydrochloride",{"trials":3011,"activeCount":60},[],{"trials":3013,"activeCount":60},[],{"trials":3015,"activeCount":60},[],{"trials":3017,"activeCount":60},[],{"intervention":3008,"totalTrials":56,"cells":3019},{"EARLY_PHASE1":3020,"PHASE1":3022,"PHASE2":3028,"PHASE3":3030,"PHASE4":3032,"NA":3034},{"trials":3021,"activeCount":60},[],{"trials":3023,"activeCount":60},[3024],{"nctId":3001,"briefTitle":3002,"status":204,"phases":3025,"primaryCompletion":3004,"completion":3004,"start":3005,"enrollment":2581,"conditions":3026,"interventions":3027},[49],[661],[2994,3008,3009],{"trials":3029,"activeCount":60},[],{"trials":3031,"activeCount":60},[],{"trials":3033,"activeCount":60},[],{"trials":3035,"activeCount":60},[],{"intervention":3009,"totalTrials":56,"cells":3037},{"EARLY_PHASE1":3038,"PHASE1":3040,"PHASE2":3046,"PHASE3":3048,"PHASE4":3050,"NA":3052},{"trials":3039,"activeCount":60},[],{"trials":3041,"activeCount":60},[3042],{"nctId":3001,"briefTitle":3002,"status":204,"phases":3043,"primaryCompletion":3004,"completion":3004,"start":3005,"enrollment":2581,"conditions":3044,"interventions":3045},[49],[661],[2994,3008,3009],{"trials":3047,"activeCount":60},[],{"trials":3049,"activeCount":60},[],{"trials":3051,"activeCount":60},[],{"trials":3053,"activeCount":60},[],{"intervention":3055,"totalTrials":56,"cells":3056},"oxymorphone hydrochloride",{"EARLY_PHASE1":3057,"PHASE1":3059,"PHASE2":3070,"PHASE3":3072,"PHASE4":3074,"NA":3076},{"trials":3058,"activeCount":60},[],{"trials":3060,"activeCount":60},[3061],{"nctId":3062,"briefTitle":3063,"status":141,"phases":3064,"primaryCompletion":3065,"completion":3065,"start":3066,"enrollment":1878,"conditions":3067,"interventions":3068},"NCT00857142","Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions",[49],"2007-12","2007-11",[2392],[3055,3069],"Opana",{"trials":3071,"activeCount":60},[],{"trials":3073,"activeCount":60},[],{"trials":3075,"activeCount":60},[],{"trials":3077,"activeCount":60},[],{"intervention":3069,"totalTrials":56,"cells":3079},{"EARLY_PHASE1":3080,"PHASE1":3082,"PHASE2":3088,"PHASE3":3090,"PHASE4":3092,"NA":3094},{"trials":3081,"activeCount":60},[],{"trials":3083,"activeCount":60},[3084],{"nctId":3062,"briefTitle":3063,"status":141,"phases":3085,"primaryCompletion":3065,"completion":3065,"start":3066,"enrollment":1878,"conditions":3086,"interventions":3087},[49],[2392],[3055,3069],{"trials":3089,"activeCount":60},[],{"trials":3091,"activeCount":60},[],{"trials":3093,"activeCount":60},[],{"trials":3095,"activeCount":60},[],{"intervention":3097,"totalTrials":56,"cells":3098},"Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories",{"EARLY_PHASE1":3099,"PHASE1":3101,"PHASE2":3112,"PHASE3":3114,"PHASE4":3116,"NA":3118},{"trials":3100,"activeCount":60},[],{"trials":3102,"activeCount":60},[3103],{"nctId":3104,"briefTitle":3105,"status":141,"phases":3106,"primaryCompletion":3107,"completion":3107,"start":3108,"enrollment":463,"conditions":3109,"interventions":3110},"NCT00913419","To Demonstrate the Relative Bioavailability of Cyclobenzaprine HCl Tablets",[49],"1988-12","1988-11",[15],[3097,3111],"Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme",{"trials":3113,"activeCount":60},[],{"trials":3115,"activeCount":60},[],{"trials":3117,"activeCount":60},[],{"trials":3119,"activeCount":60},[],{"intervention":3111,"totalTrials":56,"cells":3121},{"EARLY_PHASE1":3122,"PHASE1":3124,"PHASE2":3130,"PHASE3":3132,"PHASE4":3134,"NA":3136},{"trials":3123,"activeCount":60},[],{"trials":3125,"activeCount":60},[3126],{"nctId":3104,"briefTitle":3105,"status":141,"phases":3127,"primaryCompletion":3107,"completion":3107,"start":3108,"enrollment":463,"conditions":3128,"interventions":3129},[49],[15],[3097,3111],{"trials":3131,"activeCount":60},[],{"trials":3133,"activeCount":60},[],{"trials":3135,"activeCount":60},[],{"trials":3137,"activeCount":60},[],{"intervention":3139,"totalTrials":56,"cells":3140},"Clemastine Fumarate Tablets, 2.68 mg",{"EARLY_PHASE1":3141,"PHASE1":3143,"PHASE2":3154,"PHASE3":3156,"PHASE4":3158,"NA":3160},{"trials":3142,"activeCount":60},[],{"trials":3144,"activeCount":60},[3145],{"nctId":3146,"briefTitle":3147,"status":141,"phases":3148,"primaryCompletion":3149,"completion":3149,"start":3150,"enrollment":9,"conditions":3151,"interventions":3152},"NCT00913549","To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets",[49],"1990-01","1989-12",[2841],[3139,3153],"Tavist Tablets, 2.68 mg",{"trials":3155,"activeCount":60},[],{"trials":3157,"activeCount":60},[],{"trials":3159,"activeCount":60},[],{"trials":3161,"activeCount":60},[],{"intervention":3153,"totalTrials":56,"cells":3163},{"EARLY_PHASE1":3164,"PHASE1":3166,"PHASE2":3172,"PHASE3":3174,"PHASE4":3176,"NA":3178},{"trials":3165,"activeCount":60},[],{"trials":3167,"activeCount":60},[3168],{"nctId":3146,"briefTitle":3147,"status":141,"phases":3169,"primaryCompletion":3149,"completion":3149,"start":3150,"enrollment":9,"conditions":3170,"interventions":3171},[49],[2841],[3139,3153],{"trials":3173,"activeCount":60},[],{"trials":3175,"activeCount":60},[],{"trials":3177,"activeCount":60},[],{"trials":3179,"activeCount":60},[],{"intervention":2047,"totalTrials":56,"cells":3181},{"EARLY_PHASE1":3182,"PHASE1":3184,"PHASE2":3190,"PHASE3":3192,"PHASE4":3194,"NA":3196},{"trials":3183,"activeCount":60},[],{"trials":3185,"activeCount":60},[3186],{"nctId":2040,"briefTitle":2041,"status":141,"phases":3187,"primaryCompletion":1330,"completion":1330,"start":2043,"enrollment":2044,"conditions":3188,"interventions":3189},[49],[24],[2047,2033],{"trials":3191,"activeCount":60},[],{"trials":3193,"activeCount":60},[],{"trials":3195,"activeCount":60},[],{"trials":3197,"activeCount":60},[],{"intervention":3199,"totalTrials":56,"cells":3200},"Levetiracetam Tablets, 750 mg",{"EARLY_PHASE1":3201,"PHASE1":3203,"PHASE2":3213,"PHASE3":3215,"PHASE4":3217,"NA":3219},{"trials":3202,"activeCount":60},[],{"trials":3204,"activeCount":60},[3205],{"nctId":3206,"briefTitle":3207,"status":141,"phases":3208,"primaryCompletion":1722,"completion":1722,"start":1722,"enrollment":1733,"conditions":3209,"interventions":3211},"NCT00946751","To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions",[49],[3210],"Seizure",[3199,3212],"Keppra",{"trials":3214,"activeCount":60},[],{"trials":3216,"activeCount":60},[],{"trials":3218,"activeCount":60},[],{"trials":3220,"activeCount":60},[],{"intervention":3212,"totalTrials":56,"cells":3222},{"EARLY_PHASE1":3223,"PHASE1":3225,"PHASE2":3231,"PHASE3":3233,"PHASE4":3235,"NA":3237},{"trials":3224,"activeCount":60},[],{"trials":3226,"activeCount":60},[3227],{"nctId":3206,"briefTitle":3207,"status":141,"phases":3228,"primaryCompletion":1722,"completion":1722,"start":1722,"enrollment":1733,"conditions":3229,"interventions":3230},[49],[3210],[3199,3212],{"trials":3232,"activeCount":60},[],{"trials":3234,"activeCount":60},[],{"trials":3236,"activeCount":60},[],{"trials":3238,"activeCount":60},[],{"intervention":3240,"totalTrials":56,"cells":3241},"Bupropion HCI 300 mg Extended-Release Tablets EON",{"EARLY_PHASE1":3242,"PHASE1":3244,"PHASE2":3253,"PHASE3":3255,"PHASE4":3257,"NA":3259},{"trials":3243,"activeCount":60},[],{"trials":3245,"activeCount":60},[3246],{"nctId":3247,"briefTitle":3248,"status":141,"phases":3249,"primaryCompletion":1373,"completion":1373,"start":1722,"enrollment":1304,"conditions":3250,"interventions":3251},"NCT00861939","To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions",[49],[15],[3240,3252],"WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline",{"trials":3254,"activeCount":60},[],{"trials":3256,"activeCount":60},[],{"trials":3258,"activeCount":60},[],{"trials":3260,"activeCount":60},[],{"intervention":3252,"totalTrials":56,"cells":3262},{"EARLY_PHASE1":3263,"PHASE1":3265,"PHASE2":3271,"PHASE3":3273,"PHASE4":3275,"NA":3277},{"trials":3264,"activeCount":60},[],{"trials":3266,"activeCount":60},[3267],{"nctId":3247,"briefTitle":3248,"status":141,"phases":3268,"primaryCompletion":1373,"completion":1373,"start":1722,"enrollment":1304,"conditions":3269,"interventions":3270},[49],[15],[3240,3252],{"trials":3272,"activeCount":60},[],{"trials":3274,"activeCount":60},[],{"trials":3276,"activeCount":60},[],{"trials":3278,"activeCount":60},[],{"intervention":3280,"totalTrials":56,"cells":3281},"Glipizide 10 mg",{"EARLY_PHASE1":3282,"PHASE1":3284,"PHASE2":3294,"PHASE3":3296,"PHASE4":3298,"NA":3300},{"trials":3283,"activeCount":60},[],{"trials":3285,"activeCount":60},[3286],{"nctId":3287,"briefTitle":3288,"status":141,"phases":3289,"primaryCompletion":3290,"completion":3290,"start":3290,"enrollment":1304,"conditions":3291,"interventions":3292},"NCT00946504","To Demonstrate the Relative Bioequivalency Comparing Geneva's 10 mg Glipizide Tablets To Roerig's 10 mg Glucotrol Tablets",[49],"1992-10",[2964],[3280,3293],"Glucotrol 10 mg",{"trials":3295,"activeCount":60},[],{"trials":3297,"activeCount":60},[],{"trials":3299,"activeCount":60},[],{"trials":3301,"activeCount":60},[],{"intervention":3293,"totalTrials":56,"cells":3303},{"EARLY_PHASE1":3304,"PHASE1":3306,"PHASE2":3312,"PHASE3":3314,"PHASE4":3316,"NA":3318},{"trials":3305,"activeCount":60},[],{"trials":3307,"activeCount":60},[3308],{"nctId":3287,"briefTitle":3288,"status":141,"phases":3309,"primaryCompletion":3290,"completion":3290,"start":3290,"enrollment":1304,"conditions":3310,"interventions":3311},[49],[2964],[3280,3293],{"trials":3313,"activeCount":60},[],{"trials":3315,"activeCount":60},[],{"trials":3317,"activeCount":60},[],{"trials":3319,"activeCount":60},[],{"intervention":2054,"totalTrials":56,"cells":3321},{"EARLY_PHASE1":3322,"PHASE1":3324,"PHASE2":3330,"PHASE3":3332,"PHASE4":3334,"NA":3336},{"trials":3323,"activeCount":60},[],{"trials":3325,"activeCount":60},[3326],{"nctId":2049,"briefTitle":2050,"status":141,"phases":3327,"primaryCompletion":1330,"completion":1330,"start":2043,"enrollment":2044,"conditions":3328,"interventions":3329},[49],[24],[2054,2033],{"trials":3331,"activeCount":60},[],{"trials":3333,"activeCount":60},[],{"trials":3335,"activeCount":60},[],{"trials":3337,"activeCount":60},[],{"intervention":3339,"totalTrials":56,"cells":3340},"Azithromycin Monohydrate 600 mg",{"EARLY_PHASE1":3341,"PHASE1":3343,"PHASE2":3355,"PHASE3":3357,"PHASE4":3359,"NA":3361},{"trials":3342,"activeCount":60},[],{"trials":3344,"activeCount":60},[3345],{"nctId":3346,"briefTitle":3347,"status":141,"phases":3348,"primaryCompletion":3349,"completion":3349,"start":3350,"enrollment":2581,"conditions":3351,"interventions":3353},"NCT00865670","To Demonstrate the Relative Bioavailability of Azithromycin 600 mg Tablets Under Fed Conditions",[49],"2003-09","2003-08",[3352],"Infection",[3339,3354],"Zithromax (azithromycin dihydrate) 600 mg",{"trials":3356,"activeCount":60},[],{"trials":3358,"activeCount":60},[],{"trials":3360,"activeCount":60},[],{"trials":3362,"activeCount":60},[],{"intervention":3354,"totalTrials":56,"cells":3364},{"EARLY_PHASE1":3365,"PHASE1":3367,"PHASE2":3373,"PHASE3":3375,"PHASE4":3377,"NA":3379},{"trials":3366,"activeCount":60},[],{"trials":3368,"activeCount":60},[3369],{"nctId":3346,"briefTitle":3347,"status":141,"phases":3370,"primaryCompletion":3349,"completion":3349,"start":3350,"enrollment":2581,"conditions":3371,"interventions":3372},[49],[3352],[3339,3354],{"trials":3374,"activeCount":60},[],{"trials":3376,"activeCount":60},[],{"trials":3378,"activeCount":60},[],{"trials":3380,"activeCount":60},[],{"intervention":3382,"totalTrials":56,"cells":3383},"Desipramine Hydrochloride 100 mg",{"EARLY_PHASE1":3384,"PHASE1":3386,"PHASE2":3395,"PHASE3":3397,"PHASE4":3399,"NA":3401},{"trials":3385,"activeCount":60},[],{"trials":3387,"activeCount":60},[3388],{"nctId":3389,"briefTitle":3390,"status":141,"phases":3391,"primaryCompletion":2900,"completion":2900,"start":2900,"enrollment":9,"conditions":3392,"interventions":3393},"NCT00913822","To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride Tablets",[49],[15],[3382,3394],"Norpramin 100 mg",{"trials":3396,"activeCount":60},[],{"trials":3398,"activeCount":60},[],{"trials":3400,"activeCount":60},[],{"trials":3402,"activeCount":60},[],{"intervention":3394,"totalTrials":56,"cells":3404},{"EARLY_PHASE1":3405,"PHASE1":3407,"PHASE2":3413,"PHASE3":3415,"PHASE4":3417,"NA":3419},{"trials":3406,"activeCount":60},[],{"trials":3408,"activeCount":60},[3409],{"nctId":3389,"briefTitle":3390,"status":141,"phases":3410,"primaryCompletion":2900,"completion":2900,"start":2900,"enrollment":9,"conditions":3411,"interventions":3412},[49],[15],[3382,3394],{"trials":3414,"activeCount":60},[],{"trials":3416,"activeCount":60},[],{"trials":3418,"activeCount":60},[],{"trials":3420,"activeCount":60},[],{"intervention":3422,"totalTrials":56,"cells":3423},"Fluoxetine Hydrochloride Capsules, 40 mg",{"EARLY_PHASE1":3424,"PHASE1":3426,"PHASE2":3436,"PHASE3":3438,"PHASE4":3440,"NA":3442},{"trials":3425,"activeCount":60},[],{"trials":3427,"activeCount":60},[3428],{"nctId":3429,"briefTitle":3430,"status":141,"phases":3431,"primaryCompletion":3432,"completion":3432,"start":3433,"enrollment":463,"conditions":3434,"interventions":3435},"NCT00947076","To Demonstrate the Relative Bioavailability of Fluoxetine Hydrochloride Capsules, 40 mg",[49],"2001-04","2001-02",[15],[3422,3422],{"trials":3437,"activeCount":60},[],{"trials":3439,"activeCount":60},[],{"trials":3441,"activeCount":60},[],{"trials":3443,"activeCount":60},[],{"intervention":3445,"totalTrials":56,"cells":3446},"Haloperidol 10 mg",{"EARLY_PHASE1":3447,"PHASE1":3449,"PHASE2":3461,"PHASE3":3463,"PHASE4":3465,"NA":3467},{"trials":3448,"activeCount":60},[],{"trials":3450,"activeCount":60},[3451],{"nctId":3452,"briefTitle":3453,"status":141,"phases":3454,"primaryCompletion":3455,"completion":3455,"start":3456,"enrollment":463,"conditions":3457,"interventions":3459},"NCT00946491","To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers",[49],"1987-05","1987-04",[3458],"Psychosis",[3445,3460],"Haldol 10 mg",{"trials":3462,"activeCount":60},[],{"trials":3464,"activeCount":60},[],{"trials":3466,"activeCount":60},[],{"trials":3468,"activeCount":60},[],{"intervention":3460,"totalTrials":56,"cells":3470},{"EARLY_PHASE1":3471,"PHASE1":3473,"PHASE2":3479,"PHASE3":3481,"PHASE4":3483,"NA":3485},{"trials":3472,"activeCount":60},[],{"trials":3474,"activeCount":60},[3475],{"nctId":3452,"briefTitle":3453,"status":141,"phases":3476,"primaryCompletion":3455,"completion":3455,"start":3456,"enrollment":463,"conditions":3477,"interventions":3478},[49],[3458],[3445,3460],{"trials":3480,"activeCount":60},[],{"trials":3482,"activeCount":60},[],{"trials":3484,"activeCount":60},[],{"trials":3486,"activeCount":60},[],{"intervention":3488,"totalTrials":56,"cells":3489},"Nadolol",{"EARLY_PHASE1":3490,"PHASE1":3492,"PHASE2":3505,"PHASE3":3507,"PHASE4":3509,"NA":3511},{"trials":3491,"activeCount":60},[],{"trials":3493,"activeCount":60},[3494],{"nctId":3495,"briefTitle":3496,"status":141,"phases":3497,"primaryCompletion":3498,"completion":3498,"start":3498,"enrollment":2347,"conditions":3499,"interventions":3503},"NCT00960245","Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions",[49],"1994-07",[3500,3501,3502],"High Blood Pressure","Migraine Headaches","Chest Pain",[3488,3504],"Corgard",{"trials":3506,"activeCount":60},[],{"trials":3508,"activeCount":60},[],{"trials":3510,"activeCount":60},[],{"trials":3512,"activeCount":60},[],{"intervention":3504,"totalTrials":56,"cells":3514},{"EARLY_PHASE1":3515,"PHASE1":3517,"PHASE2":3523,"PHASE3":3525,"PHASE4":3527,"NA":3529},{"trials":3516,"activeCount":60},[],{"trials":3518,"activeCount":60},[3519],{"nctId":3495,"briefTitle":3496,"status":141,"phases":3520,"primaryCompletion":3498,"completion":3498,"start":3498,"enrollment":2347,"conditions":3521,"interventions":3522},[49],[3500,3501,3502],[3488,3504],{"trials":3524,"activeCount":60},[],{"trials":3526,"activeCount":60},[],{"trials":3528,"activeCount":60},[],{"trials":3530,"activeCount":60},[],{"intervention":3532,"totalTrials":56,"cells":3533},"Cefdinir 250 mg\u002F5 ml Oral Suspension",{"EARLY_PHASE1":3534,"PHASE1":3536,"PHASE2":3545,"PHASE3":3547,"PHASE4":3549,"NA":3551},{"trials":3535,"activeCount":60},[],{"trials":3537,"activeCount":60},[3538],{"nctId":3539,"briefTitle":3540,"status":141,"phases":3541,"primaryCompletion":2261,"completion":2261,"start":2149,"enrollment":1824,"conditions":3542,"interventions":3543},"NCT00882570","To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250mg\u002F5 ml Oral Suspension Fasting Conditions",[49],[18],[3532,3544],"Omnicef 250 mg\u002F5 ml Oral Suspension of Cefdinir",{"trials":3546,"activeCount":60},[],{"trials":3548,"activeCount":60},[],{"trials":3550,"activeCount":60},[],{"trials":3552,"activeCount":60},[],{"intervention":3544,"totalTrials":56,"cells":3554},{"EARLY_PHASE1":3555,"PHASE1":3557,"PHASE2":3563,"PHASE3":3565,"PHASE4":3567,"NA":3569},{"trials":3556,"activeCount":60},[],{"trials":3558,"activeCount":60},[3559],{"nctId":3539,"briefTitle":3540,"status":141,"phases":3560,"primaryCompletion":2261,"completion":2261,"start":2149,"enrollment":1824,"conditions":3561,"interventions":3562},[49],[18],[3532,3544],{"trials":3564,"activeCount":60},[],{"trials":3566,"activeCount":60},[],{"trials":3568,"activeCount":60},[],{"trials":3570,"activeCount":60},[],{"intervention":3572,"totalTrials":56,"cells":3573},"Rotigotine TTS",{"EARLY_PHASE1":3574,"PHASE1":3576,"PHASE2":3589,"PHASE3":3591,"PHASE4":3593,"NA":3595},{"trials":3575,"activeCount":60},[],{"trials":3577,"activeCount":60},[3578],{"nctId":3579,"briefTitle":3580,"status":204,"phases":3581,"primaryCompletion":3582,"completion":3582,"start":3583,"enrollment":3584,"conditions":3585,"interventions":3587},"NCT04183634","An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.",[49],"2020-03-16","2019-12-03",31,[3586],"Parkinson Disease",[3572,3588],"Neupro",{"trials":3590,"activeCount":60},[],{"trials":3592,"activeCount":60},[],{"trials":3594,"activeCount":60},[],{"trials":3596,"activeCount":60},[],{"intervention":3588,"totalTrials":56,"cells":3598},{"EARLY_PHASE1":3599,"PHASE1":3601,"PHASE2":3607,"PHASE3":3609,"PHASE4":3611,"NA":3613},{"trials":3600,"activeCount":60},[],{"trials":3602,"activeCount":60},[3603],{"nctId":3579,"briefTitle":3580,"status":204,"phases":3604,"primaryCompletion":3582,"completion":3582,"start":3583,"enrollment":3584,"conditions":3605,"interventions":3606},[49],[3586],[3572,3588],{"trials":3608,"activeCount":60},[],{"trials":3610,"activeCount":60},[],{"trials":3612,"activeCount":60},[],{"trials":3614,"activeCount":60},[],{"intervention":3616,"totalTrials":56,"cells":3617},"Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.",{"EARLY_PHASE1":3618,"PHASE1":3620,"PHASE2":3630,"PHASE3":3632,"PHASE4":3634,"NA":3636},{"trials":3619,"activeCount":60},[],{"trials":3621,"activeCount":60},[3622],{"nctId":3623,"briefTitle":3624,"status":141,"phases":3625,"primaryCompletion":1990,"completion":1990,"start":3626,"enrollment":1878,"conditions":3627,"interventions":3628},"NCT00864981","A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions",[49],"2005-09",[15],[3616,3629],"WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline",{"trials":3631,"activeCount":60},[],{"trials":3633,"activeCount":60},[],{"trials":3635,"activeCount":60},[],{"trials":3637,"activeCount":60},[],{"intervention":3629,"totalTrials":56,"cells":3639},{"EARLY_PHASE1":3640,"PHASE1":3642,"PHASE2":3648,"PHASE3":3650,"PHASE4":3652,"NA":3654},{"trials":3641,"activeCount":60},[],{"trials":3643,"activeCount":60},[3644],{"nctId":3623,"briefTitle":3624,"status":141,"phases":3645,"primaryCompletion":1990,"completion":1990,"start":3626,"enrollment":1878,"conditions":3646,"interventions":3647},[49],[15],[3616,3629],{"trials":3649,"activeCount":60},[],{"trials":3651,"activeCount":60},[],{"trials":3653,"activeCount":60},[],{"trials":3655,"activeCount":60},[],{"intervention":3657,"totalTrials":56,"cells":3658},"Promethazine HCl 50 mg",{"EARLY_PHASE1":3659,"PHASE1":3661,"PHASE2":3672,"PHASE3":3674,"PHASE4":3676,"NA":3678},{"trials":3660,"activeCount":60},[],{"trials":3662,"activeCount":60},[3663],{"nctId":3664,"briefTitle":3665,"status":141,"phases":3666,"primaryCompletion":3667,"completion":3667,"start":3668,"enrollment":9,"conditions":3669,"interventions":3670},"NCT00947063","To Demonstrate the Relative Bioavailability Study of Promethazine HCl 50 mg Tablets Under Fasting Conditions",[49],"2004-08","2004-07",[2841],[3657,3671],"Phenergan",{"trials":3673,"activeCount":60},[],{"trials":3675,"activeCount":60},[],{"trials":3677,"activeCount":60},[],{"trials":3679,"activeCount":60},[],{"intervention":3671,"totalTrials":56,"cells":3681},{"EARLY_PHASE1":3682,"PHASE1":3684,"PHASE2":3690,"PHASE3":3692,"PHASE4":3694,"NA":3696},{"trials":3683,"activeCount":60},[],{"trials":3685,"activeCount":60},[3686],{"nctId":3664,"briefTitle":3665,"status":141,"phases":3687,"primaryCompletion":3667,"completion":3667,"start":3668,"enrollment":9,"conditions":3688,"interventions":3689},[49],[2841],[3657,3671],{"trials":3691,"activeCount":60},[],{"trials":3693,"activeCount":60},[],{"trials":3695,"activeCount":60},[],{"trials":3697,"activeCount":60},[],{"intervention":3699,"totalTrials":56,"cells":3700},"Ribavirin 200 mg Oral",{"EARLY_PHASE1":3701,"PHASE1":3703,"PHASE2":3714,"PHASE3":3716,"PHASE4":3718,"NA":3720},{"trials":3702,"activeCount":60},[],{"trials":3704,"activeCount":60},[3705],{"nctId":3706,"briefTitle":3707,"status":141,"phases":3708,"primaryCompletion":3433,"completion":3433,"start":3709,"enrollment":2581,"conditions":3710,"interventions":3712},"NCT00960479","Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions",[49],"2001-01",[3711],"Chronic Hepatitis C",[3699,3713],"Rebetol 200 mg Oral",{"trials":3715,"activeCount":60},[],{"trials":3717,"activeCount":60},[],{"trials":3719,"activeCount":60},[],{"trials":3721,"activeCount":60},[],{"intervention":3713,"totalTrials":56,"cells":3723},{"EARLY_PHASE1":3724,"PHASE1":3726,"PHASE2":3732,"PHASE3":3734,"PHASE4":3736,"NA":3738},{"trials":3725,"activeCount":60},[],{"trials":3727,"activeCount":60},[3728],{"nctId":3706,"briefTitle":3707,"status":141,"phases":3729,"primaryCompletion":3433,"completion":3433,"start":3709,"enrollment":2581,"conditions":3730,"interventions":3731},[49],[3711],[3699,3713],{"trials":3733,"activeCount":60},[],{"trials":3735,"activeCount":60},[],{"trials":3737,"activeCount":60},[],{"trials":3739,"activeCount":60},[],{"intervention":3741,"totalTrials":56,"cells":3742},"Alprazolam Tablets, 1 mg",{"EARLY_PHASE1":3743,"PHASE1":3745,"PHASE2":3755,"PHASE3":3757,"PHASE4":3759,"NA":3761},{"trials":3744,"activeCount":60},[],{"trials":3746,"activeCount":60},[3747],{"nctId":3748,"briefTitle":3749,"status":141,"phases":3750,"primaryCompletion":3751,"completion":3751,"start":3751,"enrollment":463,"conditions":3752,"interventions":3754},"NCT00913341","To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 1 mg",[49],"1991-11",[3753],"Anxiety",[3741,3741],{"trials":3756,"activeCount":60},[],{"trials":3758,"activeCount":60},[],{"trials":3760,"activeCount":60},[],{"trials":3762,"activeCount":60},[],{"intervention":3764,"totalTrials":56,"cells":3765},"Ribavirin 200",{"EARLY_PHASE1":3766,"PHASE1":3768,"PHASE2":3778,"PHASE3":3780,"PHASE4":3782,"NA":3784},{"trials":3767,"activeCount":60},[],{"trials":3769,"activeCount":60},[3770],{"nctId":3771,"briefTitle":3772,"status":141,"phases":3773,"primaryCompletion":3774,"completion":3774,"start":3432,"enrollment":1741,"conditions":3775,"interventions":3776},"NCT00959933","Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Non-Fasting Conditions",[49],"2001-05",[3711],[3764,3777],"Rebetol 200",{"trials":3779,"activeCount":60},[],{"trials":3781,"activeCount":60},[],{"trials":3783,"activeCount":60},[],{"trials":3785,"activeCount":60},[],{"intervention":3777,"totalTrials":56,"cells":3787},{"EARLY_PHASE1":3788,"PHASE1":3790,"PHASE2":3796,"PHASE3":3798,"PHASE4":3800,"NA":3802},{"trials":3789,"activeCount":60},[],{"trials":3791,"activeCount":60},[3792],{"nctId":3771,"briefTitle":3772,"status":141,"phases":3793,"primaryCompletion":3774,"completion":3774,"start":3432,"enrollment":1741,"conditions":3794,"interventions":3795},[49],[3711],[3764,3777],{"trials":3797,"activeCount":60},[],{"trials":3799,"activeCount":60},[],{"trials":3801,"activeCount":60},[],{"trials":3803,"activeCount":60},[],{"intervention":3805,"totalTrials":56,"cells":3806},"Bupropion HCl 100 mg",{"EARLY_PHASE1":3807,"PHASE1":3809,"PHASE2":3819,"PHASE3":3821,"PHASE4":3823,"NA":3825},{"trials":3808,"activeCount":60},[],{"trials":3810,"activeCount":60},[3811],{"nctId":3812,"briefTitle":3813,"status":141,"phases":3814,"primaryCompletion":3815,"completion":3815,"start":3815,"enrollment":9,"conditions":3816,"interventions":3817},"NCT00883155","To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions",[49],"1998-10",[18],[3805,3818],"Wellbutrin 100 mg",{"trials":3820,"activeCount":60},[],{"trials":3822,"activeCount":60},[],{"trials":3824,"activeCount":60},[],{"trials":3826,"activeCount":60},[],{"intervention":3818,"totalTrials":56,"cells":3828},{"EARLY_PHASE1":3829,"PHASE1":3831,"PHASE2":3837,"PHASE3":3839,"PHASE4":3841,"NA":3843},{"trials":3830,"activeCount":60},[],{"trials":3832,"activeCount":60},[3833],{"nctId":3812,"briefTitle":3813,"status":141,"phases":3834,"primaryCompletion":3815,"completion":3815,"start":3815,"enrollment":9,"conditions":3835,"interventions":3836},[49],[18],[3805,3818],{"trials":3838,"activeCount":60},[],{"trials":3840,"activeCount":60},[],{"trials":3842,"activeCount":60},[],{"trials":3844,"activeCount":60},[],{"intervention":3846,"totalTrials":56,"cells":3847},"Imipramine Hydrochloride 50 mg",{"EARLY_PHASE1":3848,"PHASE1":3850,"PHASE2":3859,"PHASE3":3861,"PHASE4":3863,"NA":3865},{"trials":3849,"activeCount":60},[],{"trials":3851,"activeCount":60},[3852],{"nctId":3853,"briefTitle":3854,"status":141,"phases":3855,"primaryCompletion":3626,"completion":3626,"start":1328,"enrollment":2044,"conditions":3856,"interventions":3857},"NCT00946764","To Demonstrate the Relative Bioavailability of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg Imipramine Hydrochloride Tablets In Healthy Adults Volunteers Under Fasting Conditions",[49],[15],[3846,3858],"Tofranil Imipramine Hydrochloride 50 mg",{"trials":3860,"activeCount":60},[],{"trials":3862,"activeCount":60},[],{"trials":3864,"activeCount":60},[],{"trials":3866,"activeCount":60},[],{"intervention":3858,"totalTrials":56,"cells":3868},{"EARLY_PHASE1":3869,"PHASE1":3871,"PHASE2":3877,"PHASE3":3879,"PHASE4":3881,"NA":3883},{"trials":3870,"activeCount":60},[],{"trials":3872,"activeCount":60},[3873],{"nctId":3853,"briefTitle":3854,"status":141,"phases":3874,"primaryCompletion":3626,"completion":3626,"start":1328,"enrollment":2044,"conditions":3875,"interventions":3876},[49],[15],[3846,3858],{"trials":3878,"activeCount":60},[],{"trials":3880,"activeCount":60},[],{"trials":3882,"activeCount":60},[],{"trials":3884,"activeCount":60},[],{"intervention":3886,"totalTrials":56,"cells":3887},"Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions",{"EARLY_PHASE1":3888,"PHASE1":3890,"PHASE2":3903,"PHASE3":3905,"PHASE4":3907,"NA":3909},{"trials":3889,"activeCount":60},[],{"trials":3891,"activeCount":60},[3892],{"nctId":3893,"briefTitle":3894,"status":141,"phases":3895,"primaryCompletion":3896,"completion":3896,"start":3897,"enrollment":3898,"conditions":3899,"interventions":3900},"NCT00913952","To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed and Fasted Conditions",[49],"1994-06","1994-04",18,[15],[3886,3901,3902],"Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions","Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions",{"trials":3904,"activeCount":60},[],{"trials":3906,"activeCount":60},[],{"trials":3908,"activeCount":60},[],{"trials":3910,"activeCount":60},[],{"intervention":3901,"totalTrials":56,"cells":3912},{"EARLY_PHASE1":3913,"PHASE1":3915,"PHASE2":3921,"PHASE3":3923,"PHASE4":3925,"NA":3927},{"trials":3914,"activeCount":60},[],{"trials":3916,"activeCount":60},[3917],{"nctId":3893,"briefTitle":3894,"status":141,"phases":3918,"primaryCompletion":3896,"completion":3896,"start":3897,"enrollment":3898,"conditions":3919,"interventions":3920},[49],[15],[3886,3901,3902],{"trials":3922,"activeCount":60},[],{"trials":3924,"activeCount":60},[],{"trials":3926,"activeCount":60},[],{"trials":3928,"activeCount":60},[],{"intervention":3902,"totalTrials":56,"cells":3930},{"EARLY_PHASE1":3931,"PHASE1":3933,"PHASE2":3939,"PHASE3":3941,"PHASE4":3943,"NA":3945},{"trials":3932,"activeCount":60},[],{"trials":3934,"activeCount":60},[3935],{"nctId":3893,"briefTitle":3894,"status":141,"phases":3936,"primaryCompletion":3896,"completion":3896,"start":3897,"enrollment":3898,"conditions":3937,"interventions":3938},[49],[15],[3886,3901,3902],{"trials":3940,"activeCount":60},[],{"trials":3942,"activeCount":60},[],{"trials":3944,"activeCount":60},[],{"trials":3946,"activeCount":60},[],{"intervention":3948,"totalTrials":56,"cells":3949},"Diclofenac Sodium 75 mg Tablets Under Fasting Conditions",{"EARLY_PHASE1":3950,"PHASE1":3952,"PHASE2":3963,"PHASE3":3965,"PHASE4":3967,"NA":3969},{"trials":3951,"activeCount":60},[],{"trials":3953,"activeCount":60},[3954],{"nctId":3955,"briefTitle":3956,"status":141,"phases":3957,"primaryCompletion":3958,"completion":3958,"start":3897,"enrollment":3898,"conditions":3959,"interventions":3960},"NCT00913887","To Demonstrate the Relative Bioavailability of Diclofenac Sodium 75 mg Enteric-Coated Tablets Under Non-Fasting Conditions",[49],"1994-05",[2583],[3948,3961,3962],"Diclofenac Sodium 75 mg Tablets Under Fed Conditions","Voltaren 75 mg Tablets Under Fed Conditions",{"trials":3964,"activeCount":60},[],{"trials":3966,"activeCount":60},[],{"trials":3968,"activeCount":60},[],{"trials":3970,"activeCount":60},[],{"intervention":3961,"totalTrials":56,"cells":3972},{"EARLY_PHASE1":3973,"PHASE1":3975,"PHASE2":3981,"PHASE3":3983,"PHASE4":3985,"NA":3987},{"trials":3974,"activeCount":60},[],{"trials":3976,"activeCount":60},[3977],{"nctId":3955,"briefTitle":3956,"status":141,"phases":3978,"primaryCompletion":3958,"completion":3958,"start":3897,"enrollment":3898,"conditions":3979,"interventions":3980},[49],[2583],[3948,3961,3962],{"trials":3982,"activeCount":60},[],{"trials":3984,"activeCount":60},[],{"trials":3986,"activeCount":60},[],{"trials":3988,"activeCount":60},[],{"intervention":3962,"totalTrials":56,"cells":3990},{"EARLY_PHASE1":3991,"PHASE1":3993,"PHASE2":3999,"PHASE3":4001,"PHASE4":4003,"NA":4005},{"trials":3992,"activeCount":60},[],{"trials":3994,"activeCount":60},[3995],{"nctId":3955,"briefTitle":3956,"status":141,"phases":3996,"primaryCompletion":3958,"completion":3958,"start":3897,"enrollment":3898,"conditions":3997,"interventions":3998},[49],[2583],[3948,3961,3962],{"trials":4000,"activeCount":60},[],{"trials":4002,"activeCount":60},[],{"trials":4004,"activeCount":60},[],{"trials":4006,"activeCount":60},[],{"intervention":4008,"totalTrials":56,"cells":4009},"Alprazolam Tablets, 2 mg",{"EARLY_PHASE1":4010,"PHASE1":4012,"PHASE2":4021,"PHASE3":4023,"PHASE4":4025,"NA":4027},{"trials":4011,"activeCount":60},[],{"trials":4013,"activeCount":60},[4014],{"nctId":4015,"briefTitle":4016,"status":141,"phases":4017,"primaryCompletion":4018,"completion":4018,"start":4018,"enrollment":1723,"conditions":4019,"interventions":4020},"NCT00912145","To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 2 mg",[49],"1996-02",[3753],[4008],{"trials":4022,"activeCount":60},[],{"trials":4024,"activeCount":60},[],{"trials":4026,"activeCount":60},[],{"trials":4028,"activeCount":60},[],{"intervention":4030,"totalTrials":56,"cells":4031},"Leflunomide 20 mg",{"EARLY_PHASE1":4032,"PHASE1":4034,"PHASE2":4045,"PHASE3":4047,"PHASE4":4049,"NA":4051},{"trials":4033,"activeCount":60},[],{"trials":4035,"activeCount":60},[4036],{"nctId":4037,"briefTitle":4038,"status":141,"phases":4039,"primaryCompletion":4040,"completion":4040,"start":4040,"enrollment":896,"conditions":4041,"interventions":4043},"NCT00946686","To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions",[49],"2002-09",[29,4042],"Psoriatic Arthritis",[4030,4044],"Arava 20 mg",{"trials":4046,"activeCount":60},[],{"trials":4048,"activeCount":60},[],{"trials":4050,"activeCount":60},[],{"trials":4052,"activeCount":60},[],{"intervention":4044,"totalTrials":56,"cells":4054},{"EARLY_PHASE1":4055,"PHASE1":4057,"PHASE2":4063,"PHASE3":4065,"PHASE4":4067,"NA":4069},{"trials":4056,"activeCount":60},[],{"trials":4058,"activeCount":60},[4059],{"nctId":4037,"briefTitle":4038,"status":141,"phases":4060,"primaryCompletion":4040,"completion":4040,"start":4040,"enrollment":896,"conditions":4061,"interventions":4062},[49],[29,4042],[4030,4044],{"trials":4064,"activeCount":60},[],{"trials":4066,"activeCount":60},[],{"trials":4068,"activeCount":60},[],{"trials":4070,"activeCount":60},[],{"intervention":4072,"totalTrials":56,"cells":4073},"Azithromycin for Oral Suspension 200mg\u002F5mL Eon Pharma, LLC",{"EARLY_PHASE1":4074,"PHASE1":4076,"PHASE2":4087,"PHASE3":4089,"PHASE4":4091,"NA":4093},{"trials":4075,"activeCount":60},[],{"trials":4077,"activeCount":60},[4078],{"nctId":4079,"briefTitle":4080,"status":141,"phases":4081,"primaryCompletion":2043,"completion":2043,"start":3667,"enrollment":4082,"conditions":4083,"interventions":4085},"NCT00875966","Comparative Bioavailability Study of Azithromycin 200mg\u002F5mL Suspension Following a 600mg Dose Under Fed Conditions",[49],42,[4084],"Infections",[4072,4086],"Zithromax (azithromycin for oral suspension) 200mg\u002F5mL Pfizer",{"trials":4088,"activeCount":60},[],{"trials":4090,"activeCount":60},[],{"trials":4092,"activeCount":60},[],{"trials":4094,"activeCount":60},[],{"intervention":4086,"totalTrials":56,"cells":4096},{"EARLY_PHASE1":4097,"PHASE1":4099,"PHASE2":4105,"PHASE3":4107,"PHASE4":4109,"NA":4111},{"trials":4098,"activeCount":60},[],{"trials":4100,"activeCount":60},[4101],{"nctId":4079,"briefTitle":4080,"status":141,"phases":4102,"primaryCompletion":2043,"completion":2043,"start":3667,"enrollment":4082,"conditions":4103,"interventions":4104},[49],[4084],[4072,4086],{"trials":4106,"activeCount":60},[],{"trials":4108,"activeCount":60},[],{"trials":4110,"activeCount":60},[],{"trials":4112,"activeCount":60},[],{"intervention":1889,"totalTrials":56,"cells":4114},{"EARLY_PHASE1":4115,"PHASE1":4117,"PHASE2":4123,"PHASE3":4125,"PHASE4":4127,"NA":4129},{"trials":4116,"activeCount":60},[],{"trials":4118,"activeCount":60},[4119],{"nctId":1883,"briefTitle":1884,"status":141,"phases":4120,"primaryCompletion":1876,"completion":1876,"start":1886,"enrollment":1741,"conditions":4121,"interventions":4122},[49],[18],[1866,1889],{"trials":4124,"activeCount":60},[],{"trials":4126,"activeCount":60},[],{"trials":4128,"activeCount":60},[],{"trials":4130,"activeCount":60},[],{"intervention":4132,"totalTrials":56,"cells":4133},"Diclofenac Sodium 50 mg Tablets Under Fasting Conditions",{"EARLY_PHASE1":4134,"PHASE1":4136,"PHASE2":4148,"PHASE3":4150,"PHASE4":4152,"NA":4154},{"trials":4135,"activeCount":60},[],{"trials":4137,"activeCount":60},[4138],{"nctId":4139,"briefTitle":4140,"status":141,"phases":4141,"primaryCompletion":4142,"completion":4142,"start":4143,"enrollment":3898,"conditions":4144,"interventions":4145},"NCT00914160","To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets Under Non-Fasting Conditions",[49],"1993-09","1993-08",[2583],[4132,4146,4147],"Diclofenac Sodium 50 mg Tablets Under Fed Conditions","Voltaren 50 mg Tablets Under Fed Conditions",{"trials":4149,"activeCount":60},[],{"trials":4151,"activeCount":60},[],{"trials":4153,"activeCount":60},[],{"trials":4155,"activeCount":60},[],{"intervention":4146,"totalTrials":56,"cells":4157},{"EARLY_PHASE1":4158,"PHASE1":4160,"PHASE2":4166,"PHASE3":4168,"PHASE4":4170,"NA":4172},{"trials":4159,"activeCount":60},[],{"trials":4161,"activeCount":60},[4162],{"nctId":4139,"briefTitle":4140,"status":141,"phases":4163,"primaryCompletion":4142,"completion":4142,"start":4143,"enrollment":3898,"conditions":4164,"interventions":4165},[49],[2583],[4132,4146,4147],{"trials":4167,"activeCount":60},[],{"trials":4169,"activeCount":60},[],{"trials":4171,"activeCount":60},[],{"trials":4173,"activeCount":60},[],{"intervention":4147,"totalTrials":56,"cells":4175},{"EARLY_PHASE1":4176,"PHASE1":4178,"PHASE2":4184,"PHASE3":4186,"PHASE4":4188,"NA":4190},{"trials":4177,"activeCount":60},[],{"trials":4179,"activeCount":60},[4180],{"nctId":4139,"briefTitle":4140,"status":141,"phases":4181,"primaryCompletion":4142,"completion":4142,"start":4143,"enrollment":3898,"conditions":4182,"interventions":4183},[49],[2583],[4132,4146,4147],{"trials":4185,"activeCount":60},[],{"trials":4187,"activeCount":60},[],{"trials":4189,"activeCount":60},[],{"trials":4191,"activeCount":60},[],{"intervention":4193,"totalTrials":56,"cells":4194},"10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.",{"EARLY_PHASE1":4195,"PHASE1":4197,"PHASE2":4208,"PHASE3":4210,"PHASE4":4212,"NA":4214},{"trials":4196,"activeCount":60},[],{"trials":4198,"activeCount":60},[4199],{"nctId":4200,"briefTitle":4201,"status":141,"phases":4202,"primaryCompletion":4203,"completion":4203,"start":4203,"enrollment":3898,"conditions":4204,"interventions":4205},"NCT00947024","To Demonstrate the Effect of Food on the Bioavailability of Glipizide",[49],"1993-11",[2964],[4193,4206,4207],"10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.","10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.",{"trials":4209,"activeCount":60},[],{"trials":4211,"activeCount":60},[],{"trials":4213,"activeCount":60},[],{"trials":4215,"activeCount":60},[],{"intervention":4206,"totalTrials":56,"cells":4217},{"EARLY_PHASE1":4218,"PHASE1":4220,"PHASE2":4226,"PHASE3":4228,"PHASE4":4230,"NA":4232},{"trials":4219,"activeCount":60},[],{"trials":4221,"activeCount":60},[4222],{"nctId":4200,"briefTitle":4201,"status":141,"phases":4223,"primaryCompletion":4203,"completion":4203,"start":4203,"enrollment":3898,"conditions":4224,"interventions":4225},[49],[2964],[4193,4206,4207],{"trials":4227,"activeCount":60},[],{"trials":4229,"activeCount":60},[],{"trials":4231,"activeCount":60},[],{"trials":4233,"activeCount":60},[],{"intervention":4207,"totalTrials":56,"cells":4235},{"EARLY_PHASE1":4236,"PHASE1":4238,"PHASE2":4244,"PHASE3":4246,"PHASE4":4248,"NA":4250},{"trials":4237,"activeCount":60},[],{"trials":4239,"activeCount":60},[4240],{"nctId":4200,"briefTitle":4201,"status":141,"phases":4241,"primaryCompletion":4203,"completion":4203,"start":4203,"enrollment":3898,"conditions":4242,"interventions":4243},[49],[2964],[4193,4206,4207],{"trials":4245,"activeCount":60},[],{"trials":4247,"activeCount":60},[],{"trials":4249,"activeCount":60},[],{"trials":4251,"activeCount":60},[],{"intervention":4253,"totalTrials":56,"cells":4254},"Atenolol",{"EARLY_PHASE1":4255,"PHASE1":4257,"PHASE2":4268,"PHASE3":4270,"PHASE4":4272,"NA":4274},{"trials":4256,"activeCount":60},[],{"trials":4258,"activeCount":60},[4259],{"nctId":4260,"briefTitle":4261,"status":141,"phases":4262,"primaryCompletion":4263,"completion":4263,"start":4263,"enrollment":1304,"conditions":4264,"interventions":4266},"NCT00946725","To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg",[49],"2000-11",[4265,24],"Angina",[4253,4267],"Atenolol 100 mg",{"trials":4269,"activeCount":60},[],{"trials":4271,"activeCount":60},[],{"trials":4273,"activeCount":60},[],{"trials":4275,"activeCount":60},[],{"intervention":4267,"totalTrials":56,"cells":4277},{"EARLY_PHASE1":4278,"PHASE1":4280,"PHASE2":4286,"PHASE3":4288,"PHASE4":4290,"NA":4292},{"trials":4279,"activeCount":60},[],{"trials":4281,"activeCount":60},[4282],{"nctId":4260,"briefTitle":4261,"status":141,"phases":4283,"primaryCompletion":4263,"completion":4263,"start":4263,"enrollment":1304,"conditions":4284,"interventions":4285},[49],[4265,24],[4253,4267],{"trials":4287,"activeCount":60},[],{"trials":4289,"activeCount":60},[],{"trials":4291,"activeCount":60},[],{"trials":4293,"activeCount":60},[],{"intervention":4295,"totalTrials":56,"cells":4296},"Advagraf®",{"EARLY_PHASE1":4297,"PHASE1":4299,"PHASE2":4311,"PHASE3":4313,"PHASE4":4315,"NA":4317},{"trials":4298,"activeCount":60},[],{"trials":4300,"activeCount":60},[4301],{"nctId":4302,"briefTitle":4303,"status":592,"phases":4304,"primaryCompletion":4305,"completion":4305,"start":4306,"enrollment":60,"conditions":4307,"interventions":4309},"NCT03978494","Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients.",[49],"2020-05-03","2019-09-02",[4308],"Kidney Transplant",[4295,4310],"Generic tacrolimus",{"trials":4312,"activeCount":60},[],{"trials":4314,"activeCount":60},[],{"trials":4316,"activeCount":60},[],{"trials":4318,"activeCount":60},[],{"intervention":4310,"totalTrials":56,"cells":4320},{"EARLY_PHASE1":4321,"PHASE1":4323,"PHASE2":4329,"PHASE3":4331,"PHASE4":4333,"NA":4335},{"trials":4322,"activeCount":60},[],{"trials":4324,"activeCount":60},[4325],{"nctId":4302,"briefTitle":4303,"status":592,"phases":4326,"primaryCompletion":4305,"completion":4305,"start":4306,"enrollment":60,"conditions":4327,"interventions":4328},[49],[4308],[4295,4310],{"trials":4330,"activeCount":60},[],{"trials":4332,"activeCount":60},[],{"trials":4334,"activeCount":60},[],{"trials":4336,"activeCount":60},[],{"intervention":4338,"totalTrials":56,"cells":4339},"Ferric carboxymaltose",{"EARLY_PHASE1":4340,"PHASE1":4342,"PHASE2":4354,"PHASE3":4356,"PHASE4":4358,"NA":4360},{"trials":4341,"activeCount":60},[],{"trials":4343,"activeCount":60},[4344],{"nctId":4345,"briefTitle":4346,"status":141,"phases":4347,"primaryCompletion":4348,"completion":4348,"start":4349,"enrollment":4350,"conditions":4351,"interventions":4353},"NCT03399084","A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency Anemia",[49],"2019-01-15","2017-11-29",71,[4352],"Iron Deficiency Anemia",[4338],{"trials":4355,"activeCount":60},[],{"trials":4357,"activeCount":60},[],{"trials":4359,"activeCount":60},[],{"trials":4361,"activeCount":60},[],{"intervention":4363,"totalTrials":56,"cells":4364},"Azithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals",{"EARLY_PHASE1":4365,"PHASE1":4367,"PHASE2":4376,"PHASE3":4378,"PHASE4":4380,"NA":4382},{"trials":4366,"activeCount":60},[],{"trials":4368,"activeCount":60},[4369],{"nctId":4370,"briefTitle":4371,"status":141,"phases":4372,"primaryCompletion":3349,"completion":3349,"start":3350,"enrollment":2581,"conditions":4373,"interventions":4374},"NCT00866216","Comparative Bioavailability Study of 600mg Azithromycin Monohydrate Tablets Under Fasting Conditions",[49],[3352],[4363,4375],"Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc.",{"trials":4377,"activeCount":60},[],{"trials":4379,"activeCount":60},[],{"trials":4381,"activeCount":60},[],{"trials":4383,"activeCount":60},[],{"intervention":4375,"totalTrials":56,"cells":4385},{"EARLY_PHASE1":4386,"PHASE1":4388,"PHASE2":4394,"PHASE3":4396,"PHASE4":4398,"NA":4400},{"trials":4387,"activeCount":60},[],{"trials":4389,"activeCount":60},[4390],{"nctId":4370,"briefTitle":4371,"status":141,"phases":4391,"primaryCompletion":3349,"completion":3349,"start":3350,"enrollment":2581,"conditions":4392,"interventions":4393},[49],[3352],[4363,4375],{"trials":4395,"activeCount":60},[],{"trials":4397,"activeCount":60},[],{"trials":4399,"activeCount":60},[],{"trials":4401,"activeCount":60},[],{"intervention":4403,"totalTrials":56,"cells":4404},"oxymorphone",{"EARLY_PHASE1":4405,"PHASE1":4407,"PHASE2":4417,"PHASE3":4419,"PHASE4":4421,"NA":4423},{"trials":4406,"activeCount":60},[],{"trials":4408,"activeCount":60},[4409],{"nctId":4410,"briefTitle":4411,"status":141,"phases":4412,"primaryCompletion":3066,"completion":3065,"start":3066,"enrollment":4413,"conditions":4414,"interventions":4415},"NCT00857428","Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions",[49],50,[2392],[4403,4416],"Oxymorphone",{"trials":4418,"activeCount":60},[],{"trials":4420,"activeCount":60},[],{"trials":4422,"activeCount":60},[],{"trials":4424,"activeCount":60},[],{"intervention":4426,"totalTrials":56,"cells":4427},"Lisinopril 40 mg",{"EARLY_PHASE1":4428,"PHASE1":4430,"PHASE2":4440,"PHASE3":4442,"PHASE4":4444,"NA":4446},{"trials":4429,"activeCount":60},[],{"trials":4431,"activeCount":60},[4432],{"nctId":4433,"briefTitle":4434,"status":141,"phases":4435,"primaryCompletion":4436,"completion":4436,"start":4437,"enrollment":1878,"conditions":4438,"interventions":4439},"NCT00883064","To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions",[49],"2000-04","2000-03",[24],[4426,4426],{"trials":4441,"activeCount":60},[],{"trials":4443,"activeCount":60},[],{"trials":4445,"activeCount":60},[],{"trials":4447,"activeCount":60},[],{"intervention":4449,"totalTrials":56,"cells":4450},"Divalproex Sodium",{"EARLY_PHASE1":4451,"PHASE1":4453,"PHASE2":4463,"PHASE3":4465,"PHASE4":4467,"NA":4469},{"trials":4452,"activeCount":60},[],{"trials":4454,"activeCount":60},[4455],{"nctId":4456,"briefTitle":4457,"status":141,"phases":4458,"primaryCompletion":2389,"completion":2389,"start":2389,"enrollment":1304,"conditions":4459,"interventions":4461},"NCT00864006","Bioequivalence Study of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions",[49],[4460],"Seizures",[4449,4462],"Depakote DR",{"trials":4464,"activeCount":60},[],{"trials":4466,"activeCount":60},[],{"trials":4468,"activeCount":60},[],{"trials":4470,"activeCount":60},[],{"intervention":4462,"totalTrials":56,"cells":4472},{"EARLY_PHASE1":4473,"PHASE1":4475,"PHASE2":4481,"PHASE3":4483,"PHASE4":4485,"NA":4487},{"trials":4474,"activeCount":60},[],{"trials":4476,"activeCount":60},[4477],{"nctId":4456,"briefTitle":4457,"status":141,"phases":4478,"primaryCompletion":2389,"completion":2389,"start":2389,"enrollment":1304,"conditions":4479,"interventions":4480},[49],[4460],[4449,4462],{"trials":4482,"activeCount":60},[],{"trials":4484,"activeCount":60},[],{"trials":4486,"activeCount":60},[],{"trials":4488,"activeCount":60},[],{"intervention":4490,"totalTrials":56,"cells":4491},"Lisinopril 40 mg Tablet (Zestril) under fed conditions.",{"EARLY_PHASE1":4492,"PHASE1":4494,"PHASE2":4506,"PHASE3":4508,"PHASE4":4510,"NA":4512},{"trials":4493,"activeCount":60},[],{"trials":4495,"activeCount":60},[4496],{"nctId":4497,"briefTitle":4498,"status":141,"phases":4499,"primaryCompletion":4500,"completion":4500,"start":4501,"enrollment":1741,"conditions":4502,"interventions":4503},"NCT00883506","To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablet Under Fasting and Fed",[49],"2000-06","2000-05",[24],[4490,4504,4505],"Lisinopril 40 mg Tablet under fasting conditions.","Lisinopril 40 mg Tablet under fed conditions.",{"trials":4507,"activeCount":60},[],{"trials":4509,"activeCount":60},[],{"trials":4511,"activeCount":60},[],{"trials":4513,"activeCount":60},[],{"intervention":4504,"totalTrials":56,"cells":4515},{"EARLY_PHASE1":4516,"PHASE1":4518,"PHASE2":4524,"PHASE3":4526,"PHASE4":4528,"NA":4530},{"trials":4517,"activeCount":60},[],{"trials":4519,"activeCount":60},[4520],{"nctId":4497,"briefTitle":4498,"status":141,"phases":4521,"primaryCompletion":4500,"completion":4500,"start":4501,"enrollment":1741,"conditions":4522,"interventions":4523},[49],[24],[4490,4504,4505],{"trials":4525,"activeCount":60},[],{"trials":4527,"activeCount":60},[],{"trials":4529,"activeCount":60},[],{"trials":4531,"activeCount":60},[],{"intervention":4505,"totalTrials":56,"cells":4533},{"EARLY_PHASE1":4534,"PHASE1":4536,"PHASE2":4542,"PHASE3":4544,"PHASE4":4546,"NA":4548},{"trials":4535,"activeCount":60},[],{"trials":4537,"activeCount":60},[4538],{"nctId":4497,"briefTitle":4498,"status":141,"phases":4539,"primaryCompletion":4500,"completion":4500,"start":4501,"enrollment":1741,"conditions":4540,"interventions":4541},[49],[24],[4490,4504,4505],{"trials":4543,"activeCount":60},[],{"trials":4545,"activeCount":60},[],{"trials":4547,"activeCount":60},[],{"trials":4549,"activeCount":60},[],{"intervention":4551,"totalTrials":56,"cells":4552},"Indomethacin 75mg Extended-Release Capsules, Sandoz",{"EARLY_PHASE1":4553,"PHASE1":4555,"PHASE2":4564,"PHASE3":4566,"PHASE4":4568,"NA":4570},{"trials":4554,"activeCount":60},[],{"trials":4556,"activeCount":60},[4557],{"nctId":4558,"briefTitle":4559,"status":141,"phases":4560,"primaryCompletion":1770,"completion":1770,"start":1771,"enrollment":9,"conditions":4561,"interventions":4562},"NCT00858195","A Relative Bioavailability Study of 75mg Indomethacin Extended-Release Capsules",[49],[2583],[4551,4563],"Indocin 75mg SR",{"trials":4565,"activeCount":60},[],{"trials":4567,"activeCount":60},[],{"trials":4569,"activeCount":60},[],{"trials":4571,"activeCount":60},[],{"intervention":4563,"totalTrials":56,"cells":4573},{"EARLY_PHASE1":4574,"PHASE1":4576,"PHASE2":4582,"PHASE3":4584,"PHASE4":4586,"NA":4588},{"trials":4575,"activeCount":60},[],{"trials":4577,"activeCount":60},[4578],{"nctId":4558,"briefTitle":4559,"status":141,"phases":4579,"primaryCompletion":1770,"completion":1770,"start":1771,"enrollment":9,"conditions":4580,"interventions":4581},[49],[2583],[4551,4563],{"trials":4583,"activeCount":60},[],{"trials":4585,"activeCount":60},[],{"trials":4587,"activeCount":60},[],{"trials":4589,"activeCount":60},[],{"intervention":4591,"totalTrials":56,"cells":4592},"Budesonide",{"EARLY_PHASE1":4593,"PHASE1":4595,"PHASE2":4607,"PHASE3":4609,"PHASE4":4611,"NA":4613},{"trials":4594,"activeCount":60},[],{"trials":4596,"activeCount":60},[4597],{"nctId":4598,"briefTitle":4599,"status":141,"phases":4600,"primaryCompletion":4601,"completion":4601,"start":4602,"enrollment":4603,"conditions":4604,"interventions":4606},"NCT05429775","In Vivo Performance of Oral Liquid Formulations of Budesonide in the Fasted State in Healthy Subjects",[49],"2019-01-29","2018-12-26",12,[4605],"Healthy Volunteers",[4591],{"trials":4608,"activeCount":60},[],{"trials":4610,"activeCount":60},[],{"trials":4612,"activeCount":60},[],{"trials":4614,"activeCount":60},[],{"intervention":4616,"totalTrials":32,"cells":4617},"Sargramostim",{"EARLY_PHASE1":4618,"PHASE1":4620,"PHASE2":4641,"PHASE3":4643,"PHASE4":4645,"NA":4647},{"trials":4619,"activeCount":60},[],{"trials":4621,"activeCount":60},[4622,4628,4635],{"nctId":4623,"briefTitle":4624,"status":141,"phases":4625,"conditions":4626,"interventions":4627},"NCT00002008","An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia",[49],[21,27],[4616],{"nctId":4629,"briefTitle":4630,"status":141,"phases":4631,"conditions":4632,"interventions":4633},"NCT00002006","A Phase I\u002FII Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility",[49],[21,27],[4634,4616],"Zidovudine",{"nctId":4636,"briefTitle":4637,"status":141,"phases":4638,"conditions":4639,"interventions":4640},"NCT00002009","A Phase I\u002FII Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia",[49],[21,27],[4616],{"trials":4642,"activeCount":60},[],{"trials":4644,"activeCount":60},[],{"trials":4646,"activeCount":60},[],{"trials":4648,"activeCount":60},[4649,4655],{"nctId":4650,"briefTitle":4651,"status":141,"phases":4652,"conditions":4653,"interventions":4654},"NCT00002007","A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia",[53],[21,27],[4634,4616],{"nctId":4656,"briefTitle":4657,"status":141,"phases":4658,"conditions":4659,"interventions":4660},"NCT00002263","A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine",[53],[21,27],[4634,4616],{"intervention":4634,"totalTrials":8,"cells":4662},{"EARLY_PHASE1":4663,"PHASE1":4665,"PHASE2":4671,"PHASE3":4673,"PHASE4":4675,"NA":4677},{"trials":4664,"activeCount":60},[],{"trials":4666,"activeCount":60},[4667],{"nctId":4629,"briefTitle":4630,"status":141,"phases":4668,"conditions":4669,"interventions":4670},[49],[21,27],[4634,4616],{"trials":4672,"activeCount":60},[],{"trials":4674,"activeCount":60},[],{"trials":4676,"activeCount":60},[],{"trials":4678,"activeCount":60},[4679,4683],{"nctId":4650,"briefTitle":4651,"status":141,"phases":4680,"conditions":4681,"interventions":4682},[53],[21,27],[4634,4616],{"nctId":4656,"briefTitle":4657,"status":141,"phases":4684,"conditions":4685,"interventions":4686},[53],[21,27],[4634,4616],{"intervention":4688,"totalTrials":119,"cells":4689},"Octreotide",{"EARLY_PHASE1":4690,"PHASE1":4692,"PHASE2":4694,"PHASE3":4696,"PHASE4":4698,"NA":4700},{"trials":4691,"activeCount":60},[],{"trials":4693,"activeCount":60},[],{"trials":4695,"activeCount":60},[],{"trials":4697,"activeCount":60},[],{"trials":4699,"activeCount":60},[],{"trials":4701,"activeCount":60},[4702,4709],{"nctId":4703,"briefTitle":4704,"status":141,"phases":4705,"conditions":4706,"interventions":4708},"NCT00002253","A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either \"Responders\" or \"Non-Responders\" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.",[53],[4707,21],"Diarrhea",[4688],{"nctId":4710,"briefTitle":4711,"status":141,"phases":4712,"conditions":4713,"interventions":4714},"NCT00002252","A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea",[53],[4707,21],[4688],{"intervention":4716,"totalTrials":56,"cells":4717},"Recombinant human erythropoietin alfa",{"EARLY_PHASE1":4718,"PHASE1":4720,"PHASE2":4722,"PHASE3":4724,"PHASE4":4726,"NA":4728},{"trials":4719,"activeCount":60},[],{"trials":4721,"activeCount":60},[],{"trials":4723,"activeCount":60},[],{"trials":4725,"activeCount":60},[],{"trials":4727,"activeCount":60},[],{"trials":4729,"activeCount":60},[4730],{"nctId":4731,"briefTitle":4732,"status":141,"phases":4733,"primaryCompletion":4734,"completion":4734,"start":4735,"enrollment":4736,"conditions":4737,"interventions":4740},"NCT01121237","MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5",[],"2014-11","2010-02",2086,[225,4738,4739],"End-stage Renal Disease","Anaemia",[4716]]